U.S. patent application number 11/876522 was filed with the patent office on 2008-07-03 for defective sindbis viral vectors.
This patent application is currently assigned to New York University. Invention is credited to Alicia Hurtado, Daniel Meruelo.
Application Number | 20080161261 11/876522 |
Document ID | / |
Family ID | 37054122 |
Filed Date | 2008-07-03 |
United States Patent
Application |
20080161261 |
Kind Code |
A1 |
Hurtado; Alicia ; et
al. |
July 3, 2008 |
DEFECTIVE SINDBIS VIRAL VECTORS
Abstract
Disclosed herein are new defective Sindbis viral vectors made
from wild type Ar-339 Sindbis virus, with differences in replicase
and envelope proteins between JT vectors and consensus Sindbis
virus sequences, and also between JT and Ar-339 vectors. Also
disclosed are plasmids used for the production of the vectors,
methods for producing the vectors, methods for treating mammals
suffering from tumors and pharmaceutical formulations for use in
the treatment methods.
Inventors: |
Hurtado; Alicia; (New York,
NY) ; Meruelo; Daniel; (Scarborough, NY) |
Correspondence
Address: |
DARBY & DARBY P.C.
P.O. BOX 770, Church Street Station
New York
NY
10008-0770
US
|
Assignee: |
New York University
New York
NY
|
Family ID: |
37054122 |
Appl. No.: |
11/876522 |
Filed: |
October 22, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11392926 |
Mar 28, 2006 |
7303898 |
|
|
11876522 |
|
|
|
|
60666432 |
Mar 29, 2005 |
|
|
|
60755428 |
Dec 30, 2005 |
|
|
|
Current U.S.
Class: |
514/44R ;
435/320.1 |
Current CPC
Class: |
C07K 14/005 20130101;
C12N 2770/36161 20130101; C12N 7/00 20130101; C12N 2770/36132
20130101; C12N 15/86 20130101; A01K 2267/0331 20130101; A61P 35/00
20180101; A61K 35/76 20130101; C12N 2840/203 20130101; C12N
2770/36143 20130101; A61P 35/02 20180101; C12N 2770/36122 20130101;
A61P 43/00 20180101 |
Class at
Publication: |
514/44 ;
435/320.1 |
International
Class: |
A61K 31/70 20060101
A61K031/70; C12N 15/00 20060101 C12N015/00 |
Goverment Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The United States Government has certain rights to this
invention by virtue of funding received from US Public Health
Service grants CA22247 and CA68498 from the National Cancer
Institute, National Institutes of Health, Department of Health and
Human Services, and by U.S. Army grant 0C000111.
Claims
1-10. (canceled)
11. A defective Sindbis viral vector produced by the method
comprising the steps of: (a) providing a linearized replicon
plasmid comprising the nucleotide sequence consisting of the
sequence as set forth in SEQ ID NO: 36 and a linearized Helper
plasmid comprising the nucleotide sequence consisting of the
sequence as set forth in SEQ ID NO: 39; (b) transcribing said
replicon plasmid and said Helper plasmid to produce RNA; (c)
collecting the RNA transcribed in step (b) and transfecting cells
with said RNA; (d) incubating said transfected cells in step (c)
for a time and at a temperature effective for producing defective
Sindbis viral vectors; and (e) collecting said defective Sindbis
viral vectors from the medium of said transfected cells.
12. The defective Sindbis viral vector of claim 11 wherein said
vector is Mut-4.
13. The defective Sindbis viral vector of claim 11 wherein said
cells are selected from BHK-21, ES-2, ES-2/Fluc and MOSEC
cells.
14. A method for treating a mammal suffering from a tumor
comprising administering to a mammal in need of such treatment a
therapeutically effective amount of a Mut-4 defective Sindbis viral
vector.
15. A pharmaceutical formulation for treating a mammal suffering
from a tumor comprising a Mut-4 defective Sindbis viral vector and
a pharmaceutically acceptable carrier or diluent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. .sctn.
119(e) from Provisional Patent Application Ser. Nos. 60/666,432 and
60/755,428 filed Mar. 29, 2005 and Dec. 30, 2005, respectively,
which are incorporated by reference in their entirety.
FIELD OF THE INVENTION
[0003] The present invention is directed to defective Sindbis viral
vectors, plasmids used to produce such vectors, pharmaceutical
formulations containing the vectors, and methods for their
production and use to treat mammals suffering from tumors.
BACKGROUND OF THE INVENTION
[0004] Sindbis virus, a member of the alphavirus genus in the
Togaviridae family, is a single-stranded, enveloped, positive-sense
RNA virus (Strauss & Strauss, 1994). In nature, it is
transmitted via mosquito bites to mammals. Thus, as Sindbis virus
has evolved as a blood-borne vector, this hematogenous delivery
property enables Sindbis vectors to reach tumor cells throughout
the circulation (Tseng et al 2004a,b).
[0005] PCT/US02/09432 published as WO 02/076468 entitled TUMOR
THERAPY WITH ALPHAVIRUS-BASED AND HIGH AFFINITY LAMININ
RECEPTOR-TARGETED VECTORS discloses a method for treating solid
tumors in mammals using Alphavirus vectors. The method comprised
administering to a mammal harboring a tumor an amount of an
Alphavirus vector effective to treat the tumor. The vector was said
to have a preferential affinity for high affinity laminin receptors
(HALR). Tumor cells were said to express greater levels of HALR
compared to normal cells of the same lineage. The anti-tumor effect
was said to be due to the fact that Sindbis virus infection induced
apoptosis in infected cells.
[0006] PCT/US 2004/026671 for A METHOD FOR DETECTING CANCER CELLS
AND MONITORING CANCER THERAPY discloses the use of Sindbis viral
vectors to identify cancer cells in the body of a mammal and
monitor anti-cancer therapy.
[0007] With the aim of broadening the knowledge of the way Sindbis
vectors work for cancer gene therapy, two different kinds of
Sindbis vectors, SP6-H/SP6-R, derived from wild type Ar-339, and
JT-BB/JT-Rep derived from an Ar-339 laboratory adapted strain, Toto
1101 have been studied. Sindbis virus Ar-339 was first isolated in
August 1952, from a pool of mosquitoes (Culex pipiens and C.
univittatus) trapped in the Sindbis health district in Egypt
(Hurlbut 1953; Taylor and Hurlbut 1953; Frothingham 1955; Taylor et
al. 1955). Toto 1101 was made out of the heat resistant (HR) strain
initially derived from AR-339 (Burge and Pfefferkom, 1966). The
first studies done with JT vectors in animal models showed good
targeting of tumor cells and significant reduction of metastatic
implant size (Tseng et al. 2002). Further studies of these vectors
in tumor-induced SCID mice were done using the new imaging
technique of IVIS.RTM., that allows in vivo detection of viral
vector and tumor cells in the same animal. In tumor-induced SCID
mice there was a good correlation between vectors and tumor cells
(Tseng et al. 2004b). Although these positive results in vector
targeting and in vivo growth reduction of tumors and mouse
survival, which are very promising for gene therapy, survival of
all mice in these tumor models has not yet been achieved.
[0008] Therefore, what is need in the art are improved Sindbis
viral vectors for use as anti-tumor agents.
BRIEF SUMMARY OF THE INVENTION
[0009] Disclosed herein are new vectors made from wild type Ar-339
Sindbis virus, with differences in replicase and envelope proteins
between JT vectors and consensus Sindbis virus sequences, and also
between JT and Ar-339 vectors. The chimeras combining both strains
were produced and studied in tumor-induced SCID mice by the
IVIS.RTM. imaging technique. Surprisingly JT envelope proteins
targeted tumors more effectively than Ar-339 while Ar-339 replicase
showed increased efficiency in tumor reduction. To analyze which
residues would be responsible for tumor targeting, mutants of
Ar-339 E2 envelope protein were made and tested by IVIS.RTM.
imaging in ES-2 induced and tumor free mouse models. The change of
only one amino acid from Glu to Lys at position 70 of Ar-339 E2,
suppressed the ability to target metastatic tumor implants in mice.
Double E2 mutant Mut-2, with K70 and V251 did not revert the
targeting. Only when the whole sequence of JT E2 was substituted in
the Ar-339 helper was the ability of targeting metastatic tumor
implants recovered, though with less intensity. Thus, residue 70 in
the outer leaf of the E2 protein is essential for tumor specific
targeting of Sindbis vectors.
[0010] In one aspect, the present invention provides a purified,
isolated nucleic acid comprising a nucleotide sequence as set forth
in SEQ ID NO: 37 (SP6-H).
[0011] In another aspect, the present invention provides a
purified, isolated nucleic acid comprising a nucleotide sequence as
set forth in SEQ ID NO. 38 (SP6-HK 70).
[0012] In another aspect, the present invention provides a
purified, isolated nucleic acid comprising a nucleotide sequence as
set forth in SEQ ID NO. 40 (SP6-HK70-V251).
[0013] In a further aspect, the present invention provides a
purified, isolated nucleic acid comprising a nucleotide sequence as
set forth in SEQ ID NO: 39 (SP6-H-I3-K70-E181-V251).
[0014] In yet a further aspect, the present invention provides a
method for producing defective Sindbis viral vectors comprising the
steps of [0015] (a) providing a linearized replicon plasmid
comprising the nucleotide sequence as set forth in SEQ ID NO: 36
and a linearized Helper plasmid selected from SEQ ID NO: 37, SEQ ID
NO: 38, SEQ ID NO: 40 and SEQ ID NO: 39; [0016] (b) transcribing
said replicon plasmid and one Helper plasmid to produce RNA; [0017]
(c) collecting the RNA transcribed in step (b) and transfecting
cells with said RNA; [0018] (d) incubating said transfected cells
for a time and at a temperature effective for producing defective
Sindbis viral vectors; and [0019] (e) collecting said defective
Sindbis viral vectors from the medium of said transfected
cells.
[0020] These and other aspects of the present invention will be
apparent to those of ordinary skill in the art in light of the
present specification, claims and figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] FIG. 1 Sindbis virus Ar-339 cDNA cloning.
[0022] Ar-339 11703 nt genomic RNA, is illustrated schematically in
grey line, viral subgenomic promoter (P.sub.SG) nt 7334 to 7646, is
represented as grey solid box. The viral genome was cloned in 6 PCR
overlapping fragments. The viral replicase (grey dotted line) and
the subgenomic promoter were cloned in 4 PCR fragments: CDNA-1,
CDNA-2, CDNA-3A and CDNA-3B. The Sindbis subgenomic promoter and
structural proteins sequence (gray dashed line) were cloned in 2
PCR overlapping fragments CDNA-4 and CDNA-5. The position of
restriction enzyme sites in the PCR fragments that were used for
further cloning strategy are indicated.
[0023] FIG. 2. Sindbis Replicon and Helper Plasmids.
[0024] The Sindbis virus Ar-339 genome was split in two to generate
both replicon and helper plasmids. Viral sequences are represented
in grey. Virus nucleotide numbers are indicated and follow the
Strauss et al. 1984 sequence.
[0025] FIG. 3. Summary of Vector Constructions.
[0026] The first step generated the plasmid T7-pUC-PolyA#114 that
contains the bacterial segment (ampicillin resistance, pMB1
replication origin), bacteriophage promoter T7, the two
multicloning sites (MCS1 and MCS2) and the 3' end of the virus
sequence (grey dashed line). To generate the replicon, restriction
enzyme (RE) digested and gel purified DNA fragments from CDNA-1,
CDNA-2 and CDNA-3 were cloned sequentially into T7-pUC-PolyA#114.
To generate the helper, first the MfeI/BamHI fragment from the
CDNA-1 plasmid was cloned into T7-pUC-PolyA#114, and bands from
CDNA-4 and CDNA-5 were cloned into this plasmid. The sequences of
the primers used to clone the Ar-339 cDNA fragments are shown in
Table I (Appendix A).
[0027] FIG. 4(A and B). Suppression of disease progression by
Ar-339 and JT chimeric vectors. A) ES-2/Fluc cells
(1.5.times.10.sup.6) were i.p. inoculated into SCID mice on day 0.
The next day (day 1), mice were imaged using the IVIS.RTM. Imaging
System using D-luciferin as the substrate and were split into five
groups of five mice each: control, which received no vector
treatment, vector A (JT-BB/SP6-RhRLuc), vector B
(SP6-H/JT-RephRluc), vector C(SP6-H/SP6-RhRluc) and vector D
(JT-BB/JT-RephRluc). On day 5 the groups received daily i.p.
treatments of corresponding Sindbis vectors and were IVIS.RTM.
imaged on days 1, 5, 13 and 19. All vector treatments suppressed
the tumor growth on the mesentery and diaphragm and reduced the
signals on the omentum compared with control mice. B) Quantitative
analysis of the whole-body total photon counts of control and
Sindbis-treated mice. Error bars represent the SEM.
[0028] FIG. 5. Survival curves of mice treated with Ar-339 and JT
vectors. Survival curve of mice described in FIG. 4. Vector A was
the most efficient in prolonging the survival of mice bearing
ES-2/Fluc tumors.
[0029] FIG. 6 (A and B). Colocalization in peritoneal cavity of
vector C. A) Vector C (SP6-H/SP6-RhRluc) infection colocalized with
the metastasized ES-2/Fluc tumors in the peritoneal cavity as
determined by the IVIS.RTM. system. SCID mice were i.p. inoculated
with 1.5.times.10.sup.6 ES-2/Fluc cells. Five days later, while the
disease was still microscopic, inoculated mice received a single
i.p. treatment of Vector C and were imaged the next day. The first
IVIS.RTM. imaging was done by i.p. injection of Rluc substrate,
coelenterazine, followed by a 5-minute acquiring interval (left
panel). Thirty minutes after the coelenterazine injection, when the
short-lived Rluc signals faded away, Fluc substrate, D-luciferin,
was i.p. injected to determine the ES-2/Fluc tumor locations (right
panel). B) Correlation analysis of vector C shows a high
correspondence between tumor cells and vector infection in the
peritoneal cavity.
[0030] FIG. 7(A and B). Background infection of Ar-339 and JT
chimeric vectors. A) Five tumor-free mice per group were i.p.
injected on day 0 with one dose of vector A (JT-BB/SP6-RFluc),
vector B (SP6-H/JT-RepFluc) or vector C(SP6-H/SP6-RFluc) and next
day (day 1) IVIS.RTM. imaged for vector luciferase signal). The
peritoneum was removed for imaging of the peritoneal cavity and the
organs were harvested and imaged for the representative mice (rows
3 to 5). All vectors showed infection in fat tissue, and in vector
B and C groups some mice showed a low background signal on ribs but
not in organs B) Some mice per group received a second i.p.
injection of the vectors of day 2, and were IVIS.RTM. imaged in:
the peritoneal cavities (second row) and organs (bottom rows) on
day 3. Very low signals were observed in fat tissue for vectors B
and C.
[0031] FIG. (8A and B). Tumor targeting of Ar-339 and JT chimeric
vectors. A) SCID female mice were injected i.p. on day 0 with
2.times.10.sup.6 ES-2 cells/mouse. On day 4 five mice per group
were i.p. injected with one doses of vector A (JT-BB/SP6-RFluc),
vector B (SP6-H/JT-RepFluc) or vector C(SP6-H/SP6-RFluc) and next
day (day 5) IVIS.RTM. imaged for vector luciferase signals. The
peritoneum was removed for imaging of the peritoneal cavity and the
organs were harvested and imaged. All vectors targeted tumor
implants. Tumors on the peritoneum, pancreas-omentum and bowel are
circled. B) Some mice per group received a second i.p. injection of
the vectors of day 6, and the peritoneal cavities (second row) and
organs (bottom rows) were IVIS.RTM. imaged on day 7. One mouse per
group (#28, 33, 38) was not injected to serve as a luciferase
background control. Vectors B and C showed decreased
bioluminescence signals in tumors compared with the first injection
(A).
[0032] FIG. 9. SP6-1H Ar-339 E2 mutants. Amino acids changed in
Ar-339 E2 mutants Mut-1, Mut-2 and Mut-4. Sequences and residues
from the JT-BB plasmid are in black, those corresponding to Ar-339
are represented in grey.
[0033] FIG. 10(A and B). Background infection of Ar-339 E2 mutants.
A) Five tumor-free mice per group were i.p. injected on day 0 with
one dose of vector A (JT-BB/SP6-RFluc), vector C(SP6-H/SP6-RFluc),
Mut-1 (SP6-H-K70/SP6-RFluc), Mut-2(SP6-H-K70-V251/SP6-RFluc) and
Mut-4(SP6-H-I3-K70-E181-V251/SP6-RFluc). The next day, mice were
IVIS.RTM. imaged for vector luciferase signals. The peritoneum was
removed for imaging of the peritoneal cavity of representative mice
and the organs were harvested and also imaged. The E2 mutant
vectors did not show background infection of fat tissue as observed
with vectors A and C. E2 mutant organ arrays were also IVIS.RTM.
imaged at Bin 10 resolution to increase the detection limit (bottom
row), arrows point to regions with signals. B) Some mice per group
received a second i.p. injection of the vectors of day 2, organs
were harvested and IVIS.RTM. imaged. Mice circled (#17, 24, 27, 32,
and 39) were not injected to serve as luciferase background
controls. Only using high sensitivity Bin 10 resolution, low
bioluminescence signals (indicated with arrows) were detected in
mice 21, 22 and 38 of vector groups A, C and Mut-4
respectively.
[0034] FIG. 11(A and B). Tumor targeting of Ar-339 E2 mutants. A)
SCID female mice were i.p. injected on day 0 with 2.times.10.sup.6
ES-2 cells/mouse. On day 4, five mice per group were i.p. injected
with one dose of vector A (JT-BB/SP6-RFluc), vector
C(SP6-H/SP6-RFluc), Mut-1(SP6-H-K70/SP6-RFluc),
Mut-2(SP6-H-K70-V251/SP6-RFluc) or Mut-4(SP6-H-I3-K70-E
181-V251/SP6-RFluc), and the next day (day 5) IVIS.RTM. imaged for
vector luciferase signals. The peritoneum was removed for imaging
of the peritoneal cavity and the organs were harvested and imaged.
Vectors A and C efficiently targeted tumors, Mut-4 showed low
bioluminescence signals, Mut-1 and Mut-2 did not show luminescence.
For the three mutants, IVIS.RTM. images at Bin 10 resolution were
taken of full mice and organ arrays. Only at this high sensitivity
did some mice of Mut-1 and Mut-2 groups show very low residual
signals in metastatic implants (lower panels), arrows point to
regions with signals. B) Some mice per group received a second i.p.
injection of the vectors on day 6, and peritoneal cavities and
organs were IVIS.RTM. imaged on day 7. One mouse per group (#80,
85, 89, 94 and 99) was not injected to serve as luciferase
background controls. For the three E2 mutants, high sensitivity Bin
10 images were also taken. Vectors showed equivalent infection
pattern as for first injection.
[0035] FIG. 12 (A and B) Colocalization in peritoneal cavity of
vector Mut-4. A) Vector Mut-4 infection colocalized with the
metastasized ES-2/Fluc tumors in the peritoneal cavity as
determined by the IVIS.RTM. Imaging System. SCID mice were i.p.
inoculated with 1.5.times.10.sup.6 ES-2/Fluc cells. Five days
later, while the disease was still microscopic, inoculated mice
received a single i.p. treatment of vector Mut-4 and were imaged
the next day. The first IVIS.RTM. imaging was done by i.p.
injection of Rluc substrate, coelenterazine, followed by a 5-minute
acquiring interval (left panel). Thirty minutes after the
coelenterazine injection, when the short-lived Rluc signals faded
away, Fluc substrate, D-luciferin, was i.p. injected to determine
the ES-2/Fluc tumor locations (right panel). B) Correlation
analysis of vector Mut-4 shows a high correspondence between tumor
cells and vector infection in the peritoneal cavity.
[0036] FIG. 13. (A-C) Suppression of disease progression by Ar-339
and Mut-4 chimeric vectors. A) ES-2/Fluc cells (1.5.times.10.sup.6)
were i.p. inoculated into SCID mice on day 0. The next day (day 1),
mice were imaged using the IVIS.RTM. Imaging System with
D-luciferin as substrate and were split into four groups of five
mice each: control which received no vector treatment, vector D,
vector C and vector Mut-4. The groups received daily i.p.
treatments of corresponding Sindbis vectors (106 TU) and were
IVIS.RTM. imaged on days 1, 5, 13 and 19 after the start of
treatment. All vector treatments suppressed the tumor growth on the
mesentery and diaphragm and reduced the signals on the omentum
compared with control mice. Image scale Min 8.times.10.sup.3 Max
105 counts/pixel. B) Quantitative analysis of the whole-body total
photon counts of control and Sindbis-treated mice. Error bars
represent the SEM. C) Survival curve of mice.
DETAILED DESCRIPTION OF THE INVENTION
[0037] The term "about" or "approximately" means within an
acceptable error range for the particular value as determined by
one of ordinary skill in the art, which will depend in part on how
the value is measured or determined, i.e., the limitations of the
measurement system, i.e., the degree of precision required for a
particular purpose, such as a pharmaceutical formulation. For
example, "about" can mean within 1 or more than 1 standard
deviations, per the practice in the art. Alternatively, "about" can
mean a range of up to 20%, preferably up to 10%, more preferably up
to 5%, and more preferably still up to 1% of a given value.
Alternatively, particularly with respect to biological systems or
processes, the term can mean within an order of magnitude,
preferably within 5-fold, and more preferably within 2-fold, of a
value. Where particular values are described in the application and
claims, unless otherwise stated the term "about" meaning within an
acceptable error range for the particular value should be
assumed.
[0038] In accordance with the present invention there may be
employed conventional molecular biology, microbiology, and
recombinant DNA techniques within the skill of the art. Such
techniques are explained fully in the literature. See, e.g.,
Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory
Manual, Second Edition. Cold Spring Harbor, N.Y.: Cold Spring
Harbor Laboratory Press, 1989 (herein "Sambrook et al., 1989"); DNA
Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed.
1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic
Acid Hybridization [B. D. Hames & S. J. Higgins eds. (1985)];
Transcription And Translation [B. D. Hames & S. J. Higgins,
eds. (1984)]; Animal Cell Culture [R. I. Freshney, ed. (1986)];
Immobilized Cells And Enzymes [IRL Press, (1986)]; B. Perbal, A
Practical Guide To Molecular Cloning (1984); Ausubel, F. M. et al.
(eds.). Current Protocols in Molecular Biology. John Wiley &
Sons, Inc., 1994.
[0039] Amino acid residues in proteins are abbreviated as follows:
Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is Ile
or I; Methionine is Met or M; Valine is Val or V; Serine is Ser or
S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A;
Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gln or Q;
Asparagine is Asn or N; Lysine is Lys or K; Aspartic Acid is Asp or
D; Glutamic Acid is Glu or E; Cysteine is Cys or C; Trytophan is
Trp or W; Arginine is Arg or R; and Glycine is Gly or G.
[0040] As used herein, the term "tumor" refers to a malignant
tissue comprising transformed cells that grow uncontrollably.
Tumors include leukemias, lymphomas, myelomas, plasmacytomas, and
the like, and solid tumors. Examples of solid tumors that can be
treated according to the invention include sarcomas and carcinomas
such as, but not limited to: fibrosarcoma, myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, basal cell carcinoma, epidermoid
carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma,
renal cell carcinoma, hepatoma, bile duct carcinoma,
choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor,
cervical cancer, testicular tumor, lung carcinoma, small cell lung
carcinoma, bladder carcinoma, epithelial carcinoma, glioma,
astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,
pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma,
meningioma, melanoma, neuroblastoma, neuroglioma, and
retinoblastoma.
[0041] The phrase "pharmaceutically acceptable", as used in
connection with compositions of the invention, refers to molecular
entities and other ingredients of such compositions that are
physiologically tolerable and do not typically produce untoward
reactions when administered to a human. Preferably, as used herein,
the term "pharmaceutically acceptable" means approved by a
regulatory agency of the Federal or a state government or listed in
the U.S. Pharmacopeia or other generally recognized pharmacopeia
for use in mammals, and more particularly in humans.
[0042] The term "therapeutically effective" applied to dose or
amount refers to that quantity of a compound or pharmaceutical
composition that is sufficient to result in a desired activity upon
administration to a mammal in need thereof. As used herein with
respect to viral vectors of the invention, the term
"therapeutically effective amount/dose" refers to the amount/dose
of a vector or pharmaceutical composition containing the vector
that is sufficient to produce an effective anti-tumor response upon
administration to a mammal.
[0043] Described below are preferred replication defective Sindbis
viral vectors for use in the present invention termed vector C,
Mut-1, Mut-2 and Mut-4 and the plasmids used to produce them.
Mut-1, Mut-2 and Mut-4 contain mutations in the E2 envelope protein
and are alternatively referred to herein as "E2 Mutants".
[0044] The E2 mutants of the present invention were produced using
unique helper and replicase plasmids. The present invention
provides four novel helper plasmids (SP6-H (SEQ ID NO:37) SP6-H-K70
(SEQ ID NO:38), SP6-H-K70-V251 (SEQ ID NO:40) and
SP6-H-I3-K70-E181-V251 (SEQ ID NO:39)) and one replicon plasmid
(SP6-R (SEQ ID NO:36)). Helper plasmid SP6-H, which does not
contain any amino acid changes but has a different nucleotide
sequence, is set forth in SEQ ID NO:37. The 4 helper plasmids are
used to produce Vector C, Mut-1, -2 and -4 vectors, respectively,
when produced using the novel replicon plasmid.
[0045] In order to produce viral vectors in this system, two
plasmids are used, the replicon and the helper. The replicon
contains the viral replicase, the viral packaging signal, nt 945 to
nt 1075, (Weiss B et al. 1994; Frolova et al 1997); the viral
subgenomic promoter, multicloning site 1 (MCS1) to allow for the
insertion and expression of the gene of interest, and the 3' end of
the virus (nt 11394 to 11703) to allow viral (-) strand RNA
synthesis. A second multicloning site (MCS2) allows for the
linearization of the plasmid for in vitro transcription.
[0046] The helper plasmid contains the first 425 nt of the virus,
followed by the 3' end of the virus from nt 7334 to nt 11703 which
includes the subgenomic promoter, the capsid and the viral envelope
proteins (E3, E2, 6K and E1) and the 3' end (nt 11394 to
11703).
[0047] Both plasmids share the following viral sequences: the first
425 nt and the 309 nt of the 3' end and the sub genomic
promoter.
[0048] Both plasmids have several non-viral elements in common, the
replication origin (rep pMB1) and the Ampicillin resistance gene
from the pUC cloning plasmid; the promoter for in vitro
transcription (T7 or SP6) and the MCS2. In the construction process
a plasmid containing the pUC sequences, SP6 or T7 promoter, the
multicloning sites, and the 3' viral end, which are common to both
vectors, was first generated. The specific viral sequences were
then cloned into this plasmid (FIG. 3).
[0049] In order to produce the viral vectors of the present
invention, one pair of plasmids are linearized using restriction
enzymes such as PacI, NotI, or XhoI, transcribed in vitro, the RNAs
collected and electroporated into cells. For in vitro
transcription, a promoter is inserted before the Sindbis viral
sequences. Preferably, the promoter is a bacteriophage promoter,
for us with its respective RNA polymerase such as SP6 or T7 (Ambion
Austin, Tex.).
[0050] Cells for use in the present invention include BHK-21 cells
(available from the American Type Culture Collection, ATCC,
Manassas, Va. as CRL 6281), ES-2 cells, (ATTC, CRL 1978), ES-2/Fluc
cells that were derived from the ES-2 line by transfection of a
plasmid, pIRES2-Luc/EGFP and the MOSEC cell line (clone ID8). The
transcribed RNAs (i.e., one helper and one replicon plasmid) are
electroporated into the cells at a concentration ranging between
about 0.75 mg/mL and about 1.25 mg/mL. The ratio of viral RNA to
cell concentration ranges between about 30-50 .mu.g RNA per
6.times.10.sup.6 cells. Electroporation is performed using
equipment commercially available from e.g., Bio Rad (Hercules,
Calif.)
[0051] The transfected cells are fed medium containing 5% fetal
bovine serum (FBS) and incubated at 37.degree. C. for about 12
hours. The medium is then discarded, replaced with 9 ml of Opti-MEM
I medium (GIBCO-BRL Invitrogen, San Diego Calif.) and incubated at
about 37.degree. C. for about 24 hours. Then, supernatents are
collected and centrifugated at 2,400 rpm (1,500 g) for 15 min to
eliminate cell debris. Clear supernatants, containing the viral
vector, were collected, aliquoted and stored at -80.degree. C.
[0052] The viral vectors can be used as anti-tumor agents as
described in International Application No. PCT/US02/09432 published
as WO 02/076468. Although the Mut-1 vectors do not bind to the high
affinity laminin receptors (HALR), they are useful as controls and
to monitor non-viral effects of the vectors. Since Mut-1 vectors do
not enter cells, the contribution of host factors in the
anti-cancer response can be studied.
[0053] The plasmids of the present invention can be used to
transfer of cells and create packaging cell lines for the
continuous production of defective Sindbi viral vectors as
described in copending Ser. No. 10/983,432 and in Paper Example 1
below.
[0054] The amount of viral vectors produced may be determined as
described below in the Examples. Briefly, clear supernatants are
serial diluted in Opti-MEM I medium and 300 .mu.L of each vector
dilution are added to a 35 mm well in 12-well plates, containing
2.times.10.sup.5 cells. After incubation for 1 hour at room
temperature, the cells are washed with PBS (Phosphate buffered
saline) and incubated with 2 mL of .alpha.MEM at 37.degree. C. for
about 24 hours. Media is removed, cells are washed with PBS and
cell lysates are prepared and assayed for the different reporter
activity: .beta.-galactosidase, firefly luciferase or Renilla
luciferase. Vector titers were estimated as the highest dilution
having detectable reporter activity. Detection of reporter
activities is described in Example 2.
[0055] Viral vectors can be produced by linearizing helper and
replicon plasmids after the polyA sequence, followed by separately
performed in vitro transcription reactions. Usually, 1.6 .mu.g of
plasmid yields 15-25 .mu.g of mRNA/reaction. Then 30-50 .mu.g of
both RNAs are co-electroporated into 6.times.10.sup.6 BHK-21 cells,
which are then incubated in 10 ml of .alpha.MEM containing 5% FBS
at 37.degree. C. for about 12 h. Then, the medium is replaced with
9 ml of Opti-MEM I medium (GIBCO-BRL Invitrogen, San Diego Calif.)
supplemented with 0.7 .mu.M CaCl.sub.2, cells are incubated at
37.degree. C. for about 24 h, supernatants collected and
centrifuged at .apprxeq.1,500 g for 15 min to eliminate cell
debris. The procedure can be scaled up using the following
electroporation ratios: 5-8 .mu.g helper and replicon mRNA's per
106 BHK-21 and 9 mL Ca-Opti-MEM media per reaction.
[0056] The viral vectors of the present inventions have the
following properties which are summarized in Strauss and Strauss
1994. Briefly, as Alphaviruses replicate exclusively in the
cytoplasm, there is no possibility of adventitious splicing.
Because they are replication incompetent and packaging defective,
the vectors are incapable of spread by reinfection. The vector
replicates to high copy number inside the cell, and large
quantities of mRNA are produced, leading to production of large
amounts of the protein of interest
[0057] Viral vectors obtained as described herein can be formulated
in a pharmaceutical composition for administration to a patient. As
used herein, a "pharmaceutical composition" includes the active
agent, i.e., the viral vector, and a pharmaceutically acceptable
carrier, excipient, or diluent. The phrase "pharmaceutically
acceptable" refers to molecular entities and compositions that are
physiologically tolerable and do not typically produce an allergic
or similar untoward reaction, such as gastric upset, dizziness and
the like, when administered to a human. Preferably, as used herein,
the term "pharmaceutically acceptable" means approved by a
regulatory agency of the Federal or a state government or listed in
the U.S. Pharmacopeia or other generally recognized pharmacopeia
for use in animals, and more particularly in humans. The term
"carrier" refers to a diluent, adjuvant, excipient, or vehicle with
which the compound is administered. Such pharmaceutical carriers
can be sterile liquids, such as water and oils, including those of
petroleum, animal, vegetable or synthetic origin, such as peanut
oil, soybean oil, mineral oil, sesame oil and the like. Water or
aqueous saline solutions and aqueous dextrose and glycerol
solutions are preferably employed as carriers, particularly for
injectable solutions. Suitable pharmaceutical carriers are
described in "Remington's Pharmaceutical Sciences" by E. W.
Martin.
[0058] For human therapy, the viral vectors of the present
invention may be prepared in accordance with good manufacturing
process (GMP) standards, as set by the Food & Drug
Administration (FDA). Quality assurance (QA) and quality control
(QC) standards will include testing for replication competent virus
(if the virus vector is replication defective), activity (colony
forming units [CFU] per number of viral particles, tested by
induction of apoptosis or cytopathic effect (CPE), or by expression
of a marker gene such as .beta.-galactosidase), toxicity, and other
standard measures.
[0059] In order to treat the tumors, the pharmaceutical composition
is administered by any route that will permit homing of the vector
to the tumor cells. Preferably, administration is parenteral,
including, but not limited to, intravenous, intra-arteriole,
intramuscular, intradermal, subcutaneous, intraperitoneal,
intraventricular, and intracranial administration. As disclosed
herein, viral vectors can be also administered to the tumor-bearing
animal via intranasal or oral route (see Hardy, In: The
Arbiviruses: Epidemiology and Ecology, Ch. 4, pp. 87-126).
Importantly, however, in contrast to other viral vectors in gene
therapy, administration of the Sindbis vectors of the invention
need not be locally to the tumor. Indeed, one of the advantages of
this invention is the high specificity and affinity of the vector
for cancer cells, even micrometastases that cannot be resected or
located by standard techniques (e.g., CAT scanning, MRI scanning,
etc.).
[0060] In the therapeutic treatments of the invention, a
therapeutically effective amount of the vector is administered to a
patient. As used herein, the term "therapeutically effective
amount" means an amount sufficient to reduce by at least about 15
percent, preferably by at least 50 percent, more preferably by at
least 90 percent, and most preferably prevent, a clinically
significant deficit in the activity, function and response of the
host. Alternatively, a therapeutically effective amount is
sufficient to cause an improvement in a clinically significant
condition in the host. Specifically, a therapeutically effective
amount will cause one or more of the following: apoptosis of tumor
cells; necrosis of tumor cells; elimination or prevention of tumor
metastases; reduction in the rate of tumor growth; reduction in
tumor size or tumor shrinkage; scab formation over cutaneous tumor;
elimination of the tumor; remission of the cancer; an increase in
the time for reappearance of the cancer; and increased time of
survival of the patient. The frequency and dosage of the vector
therapy can be titrated by the ordinary physician using standard
dose-to-response techniques, but generally will be in the range of
from about 10.sup.6 to about 10.sup.12 viral vector particles per
dose administered daily, weekly, biweekly, or monthly at least
twice and preferably at least three times.
[0061] In order to explore if wild type Sindbis would improve the
vector systems, four vectors were generated combining the helper
and replicase segments of both strains (JT-BB/SP6-R; SP6-H/JT-Rep;
SP6-H/SP6-R; JT-BB/JT-Rep) and tumor size reduction and survival in
tumor-induced SCID mice was studied. Unexpectedly, it was found
that those vectors carrying Ar-339 helper (SP6-H) were less
efficient in targeting tumors than the JT vectors and that those
carrying Ar-339 replicase (JT-BB/SP6-R and SP6-H/SP6-R) were more
efficient in tumor reduction. To study the surprising phenotype of
the helper, both viral sequences were analyzed and compared. One
amino acid difference was found in the capsid protein (Pro 67
(JT-BB) to Gln (Ar-339)); three amino acid changes in envelope
protein E1 (Ala.sub.72 (JT-BB) to Val (Ar-339), Gly.sub.75 (JT-BB)
to Asp (Ar-339) and Ser.sub.237 (JT-BB) to Ala (Ar-339)) and four
changes in envelope protein E2 (Ile.sub.3(JT-BB) to Thr(AR-339);
Lys.sub.70(JT-BB) to Glu(Ar-339); Glu.sub.181(JT-BB) to Lys(Ar-339)
and Val.sub.251(JT-BB) to Ala(Ar-339)). To determine which amino
acids were critical for the vector properties, different chimeras
from both vectors were generated containing mixed sequences from
both strains. The analysis in animal models showed that the Ar-339
E2 envelope protein sequence was primarily responsible for tumor
metastases targeting although the optimum amino acid pattern was
not defined. To address this question, vectors were generated
containing sequences with mixed combinations of the four amino
acids in E2, for JT and Ar-339, and tested by IVIS.RTM. imaging in
ES-2 induced and tumor-free mouse models. Surprisingly, the change
of only one amino acid from Glu to Lys at position 70 of Ar-339 E2,
suppressed the ability to target metastatic tumor implants in mice
and also showed no fat tissue background. This result was
unexpected, considering that this mutant (Mut-1) repeatedly showed
titers equivalent to the Ar-339 vector when measured in ES-2
cultured cells. Double mutant Mut-2, with K70 and V251 did not
revert the targeting. Only when the whole sequence of JT E2 was
substituted in the Ar-339 helper was the ability to target
metastatic tumor implants recovered, a though with less intensity.
Thus, residue 70 in the outer leaf of the E2 protein is essential
for tumor specific targeting of vectors.
[0062] Described herein are amino acids of Sindbis viral vectors
involved in specific infection of metastatic tumor implants in the
mouse peritoneal cavity. Sequence analysis of cloned Ar-339 and JT
viral vectors has been an important tool for the discovery of these
amino acids.
[0063] The sequence analysis comparison with the published Strauss
sequence, revealed 2 or 3 amino acid changes in viral replicase for
JT and Ar-339 respectively. The Ar-339 nsP1 Ile 441 is a reverse
mutation to an alphavirus conserved residue; this amino acid may
also be related to viral adaptation to BHK-21 tissue culture.
Ar-339 replicase is more efficient in suppression of disease
progression than JT, the change from polar Cys in JT to aliphatic
residue, Ile 441, may play a role in enhancing replicase activity.
Interestingly, both JT and Ar-339 vectors have the same 2 amino
acid changes in nsP2 protein versus the Strauss sequence. JT and
Ar-339 nsP2 residues are more conserved among the Sindbis-like
Alphavirus group.
[0064] Comparing the Strauss sequence with the region coding for
the structural part of the JT and Ar-339 vectors, the changed amino
acids were found mainly in the viral spike, although in different
residues, suggesting a different evolutionary lineage of both
strains. E1 D75 and A237 of Ar-339 are highly conserved in
Sindbis-like alphaviruses; all viruses in this group carry D75.
There is no virus in the group that has serine at 237, which only
occurs in the JT vector. These data suggest that E1 G75 and S237 of
JT vector may more likely be point mutations that arose in this
laboratory strain. Further studies with E1 mutants should reveal
the implication of these E1 residues in the specific tumor
targeting of the viral vector. Most of the sequence variabilities
have been found at the E2 envelope protein in the leaf-like domain
at the viral spike; these residues are also poorly conserved in the
Sindbis-like alphavirus group. The role of these E2 spike mutations
in mouse tumor models in vivo was examined.
[0065] The fact that the Mut-1 vector shows the same titer as the
Ar-339 vector in ES-2 cells, but does not efficiently infect ES-2
metastatic tumor implants in mice, represents a powerful tool for
the study and the improvement of Sindbis vectors for gene therapy.
One cause of the loss of tumor targeting in vivo could be a reduced
stability of the vector in mice. Alignment of protein sequences
among 17 different viruses of the Sindbis-like alphavirus group
showed that ten out of the 17 members have a gap in Sindbis E2
residues 68-71, including Semliki Forest virus (SFV) which has a
comparable structure to Sindbis virus. The viral spike is composed
of three E1-E2 heterodimers that lean against each other. There is
a gap between the base of neighboring E1-E2 heterodimers which
would allow E2 to move out of the center of the spike during fusion
(Zhang et al. 2002). In addition, previous studies with stable
deletion mutants in the E2 receptor binding domain, also show
equivalent in vitro titers but drastic reduction of infectivity in
live Aedes aegypti mosquitoes (Myles et al. 2003). Without wishing
to be bound by theory, it is believed that these data suggest that
there is structural flexibility in this area of the spike,
therefore, alterations in residue 70 shouldn't be critical for
Mut-1 vector stability in vivo. The loss of vector infectivity
would be more likely to occur via a decrease in cell binding
affinity, especially in vivo, where the environmental conditions
for vector infection are more restrictive.
[0066] In Sindbis and Semliki Forest virus (SFV), the residues
involved in host cell fusion and binding to cellular receptors are
located in the viral spike. It has been described that only one
change from the small non-polar Valine, at position 75, to the
acidic Aspartic acid in E1 SFV spike subunit, modifies the
cell-cell fusion properties of the virus (Levy-Mintz and Kielian,
1991). Amino acids in these E1 and E2 spike domains are, thus,
important in spike configuration and virus infectivity.
[0067] The vector Ar-339, having hydrophobic (V72), and acidic
(D75) residues in E1 and a glutamic acid (E70) in E2 protein, is
able to efficiently target tumor cells in vivo. In Mut-1, in which
E2 residue 70 is changed to lysine, there is a change in polarity
and charge of the amino acid that would change the conformation of
the spike and so the cell binding properties of the vector. This
hypothesis is supported by the difference in cell tropism observed
in vitro between Mut-1 and Ar-339. Only the recovery of the full
sequence of JT-BB E2 in Mut-4 results in higher titers in BHK-21
cells. If these differences were observed in vitro, where the
conditions for cell binding are optimized, it is possible that in
vivo factors involved in cell-vector interactions might be able to
prevent vector adherence to the viral receptor. Ar-339 and Mut-1
vectors have the same titer in ES-2 cells in vitro, but in mouse
metastatic implants, where ES-2 cells are in a different
environments and could have receptor variations, small affinity
differences between both vectors are revealed.
[0068] The present invention is described further below in examples
which are intended to describe the invention without limiting the
scope thereof.
[0069] In the examples below, the following materials and methods
were used.
EXAMPLE 1
Sindbis cDNA Cloning
[0070] Common Techniques
[0071] Virus Propagation
[0072] Sindbis virus strain Ar-339 (Original) was obtained from
ATCC (Manassas, Va., Item #VR-68) and propagated on a secondary
chicken embryo fibroblast cell line, CEF. Cells were cultured in
EMEM media (BioWhittaker, cat#12-684) supplemented with 10% Fetal
bovine sera, NaHCO.sub.3 1.5 g/l; 1-Glutamine, 292 mg/l and
Penicillin/Streptomycin, 100 U/ml. Two T-75 flasks with 80%
confluent CEF cell monolayers, were infected with
2.5.times.10.sup.7 pfu and 5.times.10.sup.7 pfu, respectively, of
Sindbis virus Ar-339, diluted in 1 ml of Opti-Mem I media
(GIBCO-BRL Invitrogen, San Diego Calif.; cat#31985-070)
supplemented with 0.7 .mu.M CaCl.sub.2. Virus-infected cells were
incubated at 37.degree. C. for 1 h, 10 ml of EMEM media/flask
added, and cells were incubated overnight at 37.degree. C.
Supernatants containing the Sindbis "innocula" were harvested and
stored at -80.degree. C. until used in further infections. CEF
cells were collected for total RNA extraction.
[0073] RNA Extraction
[0074] 5 T-75 flasks with 90% confluent CEF monolayers were
incubated 1 h at 37.degree. C. with 1:100; 1:20; 1:10; and 1:5
dilutions (in Ca-OPTI-MEM media) of previously obtained "Sindbis
innocula". Ten ml of EMEM media/flask was then added and incubated
overnight at 37.degree. C. After collecting the supernatant, 2 ml
of Trizol (Invitrogen, San Diego, Calif.; cat #15596-018) per flask
was added to the infected cells, the extract collected and stored
at -80.degree. C. Total RNA from infected cells was prepared
following the manufacturer's (Trizol) protocol. Briefly, 1 ml of
Trizol cell extract was vortexed for 15 seconds, 200 .mu.L of
chloroform added, vortexed, spun at 15,000 g for 10 min at room
temperature (rt), the aqueous upper phase transferred to a clean
tube, 750 .mu.L of isopropanol added, incubated at rt for 15 min,
spun again, the supernatant removed and the pellet washed with
ethanol (70% in DEPC water). The pellet was air dried at rt for
5-10 min, and resuspended in 50 .mu.L of DEPC water.
[0075] Sindbis c-DNA Cloning. Sindbis virus RNA was cloned in 6
overlapping fragments (CDNA-1, CDNA-2, CDNA-3A, CDNA-3-B, CDNA-4
and CDNA-5) into sequencing plasmid pCR4Blunt-TOPO (Invitrogen, San
Diego Calif.; cat#45-0245). The position of the fragments is shown
in FIG. 1 and the sequences of the primers used are shown in Table
I (Appendix A). The primers were designed to take advantage of the
unique restriction sites of the virus. In primer SV-C3R RE XbaI was
introduced to allow CDNA-3 cloning. For each fragment the RT and
the PCR reactions were performed with the same pair of primers. The
cloning procedure was the same for all of the fragments except for
the conditions of the PCR cycles.
[0076] Reverse transcriptase (RT) reactions were performed with: 5
.mu.g from total RNA from infected cells, reaction buffer
(1.times.); forward and reverse specific primers (2.5 .mu.M/each);
dNTPs (1 mM); DTT (5 mM) and 15 u of ThermoScript.TM. RNase
H.sup.-Reverse Transcriptase (Invitrogen, cat#12236-014), in a
final volume of 20 .mu.L. RT was diluted 1:1 in distilled water
prior to use in PCR.
[0077] The Pfx-PCR reactions were performed with 1 .mu.L of RT
reaction, reaction buffer (1.times.), MgSO.sub.4(1 mM), dNTPs (0.3
mM/each), forward and reverse primers (0.3 .mu.M/each) and 1 U
Platinum Pfx DNA Polymerase (Invitrogen, cat#11708-013) in final
volume of 25 .mu.l. RT and PCR reactions were performed in an
Eppendorf "Mastercycler Gradient" Thermal Cycler. Taq-PCR reactions
contained reaction buffer (1.times.); dNTP's (200 .mu.M), forward
and reverse primers (0.5 .mu.M/each) and 1 u Taq-DNA-polymerase
(Fisher Scientific, Pittsburgh, Pa., cat#FB 600025) in a final
volume of 20 .mu.l. In both cases PCR products were analyzed by
electrophoresis in 1% agarose gels and DNA bands cut out and
purified with a QIAEXII gel extraction kit (Qiagen, Valencia
Calif.; cat# 20021)
[0078] All enzymes were purchased from New England Biolabs (NEB,
Beverly, Mass.). After digestions with restriction enzymes (RE),
extracted DNAs were CIP dephosphorylated (1 h at 37.degree. C.)
and/or phosphorylated with T4-Polynucleotide-Kinase (1 h,
37.degree. C.), enzymes were inactivated (70.degree. C., 10 min or
65.degree. C. 20 min) and reactions were run in 1% agarose gels.
Bands were cut out, extracted, and quantified by gel
electrophoresis by comparison with bands of known DNA
concentration. Ligations were carried out with T4-DNA-Ligase (NEB)
(16.degree. C. 14 h) or with the Quick ligation kit (NEB) (5 min at
room temperature (rt)). Transformations were performed using
RapidTrans.TM. TAMI extra competent E. coli (Active Motif,
Carlsbad, Calif.; cat#11099). After transforming E. coli with the
ligations, the first screening of positive bacteria was done by
Taq-PCR of E. coli colonies. Positive plasmids were checked by
restriction enzymes. Sequencing was done at the Skirball Institute
of Biomolecular Medicine, NYU.
[0079] CDNA-1 plasmid. RT reaction was performed with primers
CDNA-1F/CDNA1-R at 55.degree. C. 1 h. Two Pfx-PCR were performed:
94.degree. C. 5 min; 35 cycles [94.degree. C. 30 s; 66.degree. C.,
30 s (band D) or [67.degree. C., 30 s; 72.degree. C., 2.5 min and
72.degree. C., 2.5 min](band E). PCR products were run in 1%
agarose gels and both 2.2 Kb bands, D and E, were isolated and
cloned separately into the pCR4Blunt-TOPO plasmid. Positive
colonies were screened using the same PCR conditions with
65.degree. C. as the annealing temperature and Taq-DNA-Polymerase.
Two plasmids were selected (one from each PCR band) and the PCR
band D in plasmid CDNA-1_Topo#64 was completely sequenced. The
sequence was compared to the Ar-339 sequence published by Strauss
et al., Virology 133, 1984. The differences found were compared
with the sequences of PCR band E. Identical differences were found
in bands D and E to confirm that they came from the virus and not
from PCR mutations.
[0080] CDNA-2 plasmid. The Reverse transcriptase reaction was
performed with primers CDNA-2F/CDNA-2R for 1 h at 55.degree. C.
Three PCR in gradient 94.degree. C., 5 min; 35 cycles of
[94.degree. C., 30 s; 64.7.degree. C., 30 s (band 1); or 66.degree.
C., 30 s (band 2); or 67.degree. C., 30 s (band 3); 72.degree. C.,
2.5 min] and 72.degree. C., 2.5 min. After cloning the 2 kb bands
separately in pCR4Blunt-TOPO, PCR screening of colonies was done at
an annealing temperature of 64.5.degree. C. Band 2 in plasmid
CDNA-2#213 was fully sequenced, and any mutations found were
checked by comparison with the sequences of PCR bands 1 and 3.
[0081] CDNA-3A plasmid. Three RT reactions were performed in
gradient with primers CDNA-3F/SV-6932R at 53.2.degree. C.,
55.5.degree. C. and 60.8.degree. C. respectively for 1 h 30 min.
Three Pfx PCR were performed with 1/L of each RT, respectively:
94.degree. C., 5 min; 35 cycles of [94.degree. C., 30 s; 53.degree.
C., 30 s; 72.degree. C., 3 min] and 72.degree. C. 3 min. The 2.68
kbp bands T, U and V were cloned separately and band V in plasmid
C3A_Topo#735 was fully sequenced. No changes were found compared
with the published Ar-339 sequences (Strauss et al. 1984).
[0082] CDNA-3B plasmid. RT reaction was performed with primers
SV-6882F/SV-C3R at 60.8.degree. C. for 1 h 30 min. Three Pfx-PCR in
gradient were performed with 94.degree. C., 5 min; 35 cycles of
[94.degree. C., 30 s; 55.3.degree. C., 30 s (band J); or 56.degree.
C., 30 s (band K); or 58.3.degree. C. 30 s (band L); 72.degree. C.,
1 min] and 72.degree. C., 2 min. The three 774 bp bands were cloned
separately and band L, in plasmid C3B-Topo#334, was fully
sequenced. The mutations found were confirmed by sequencing bands J
and K.
[0083] CDNA-3 (CDNA-3A+3B) plasmid. HpaI RE is not unique in the
Sindbis sequence, so in order to clone CDNA3A and CDNA3B fragments
into the new reporter vector, it was necessary to generate first a
Topo plasmid containing both sequences, and then clone fragment
CDNA-3 (CDNA-3A+3B) in the AvrII/XbaI site. Plasmid C3B-Topo#334
was HpaI and SacI digested and the 774 bp viral band was isolated
from the agarose gel and ligated (T4-DNA-Ligase 16.degree. C. 14 h)
to HpaI/SacI digested C3A_Topo#735 plasmid. Transformants were
screened by PCR with Taq-Polymerase, and primers CDNA-3F, SV-C3R
at: 94.degree. C., 10 min; 35 cycles of [94.degree. C. 30 s;
55.degree. C., 30 s; 72.degree. C., 3 min] and 72.degree. C. 2 min.
The positive plasmid was named C3A+B_Topo#810, and the junctions
were sequenced.
[0084] CDNA-4 plasmid. The RT reaction was performed with primers
CDNA-4F/CDNA4-R at 52.degree. C. for 1 h 30 min. Three PCRs were
performed in gradient with 94.degree. C., 5 min; 35 cycles of
[94.degree. C., 45 s; 49.7.degree. C., 30 s (band M); or 55.degree.
C., 30 s (band N); or 57.2.degree. C., 30 s (band O); 72.degree. C.
2.5 min] and 72.degree. C. 2.5 min. The 2 kbp bands were isolated
and cloned separately, band N in plasmid CDNA-4_Topo#422 was fully
sequenced. The mutations found were confirmed by sequencing bands M
and O.
[0085] CDNA-5 plasmid. RT reactions performed with primers
CDNA-5F/CDNA5-R at 49.7.degree. C. for 1 h 30 min. Three PCR were
made in gradient with 94.degree. C., 5 min; 35 cycles of
[94.degree. C., 30 s; 46.8.degree. C., 30 s (band Q); or
48.6.degree. C., 30 s (band R); or 50.5.degree. C., 30 s (band S);
72.degree. C. 2 min] and 72.degree. C., 2 min. The 2.35 kbp bands
were cloned separately and band S in plasmid CDNA-5_Topo#525 was
fully sequenced. The mutations found were confirmed by sequencing
bands Q and R. Vectors construction.
[0086] Polylinker cloning in pUC plasmid. In summary, the SP6 and
T7 Polylinker bands were constructed out of primers in two
fragments, a 5' end containing the SP6 promoter (primer pairs
Poly1-SP6(+)/Poly-2(-)) or T7 promoter (primers
Poly1-T7(+)/Poly-2(-)) and a common 3' end (primers
Poly-3(+)/Poly-4(-)) the sequences of the primers are given in
Table II (Appendix A). 5' and 3' bands were digested and ligated to
generate the polylinker and then were ligated to the AflIII/AatII
pUC band containing the E. coli replication origin and Ampicillin
resistance gene to generate T7-pUC or SP6-pUC plasmids.
[0087] T7-pUC plasmid. Two separate reactions were performed with
primers pairs Poly1-T7(+)/Poly-2(-) or Poly-3(+)/Poly-4(-). For
both reactions, conditions were: primers (5 .mu.g each), buffer
(1.times.), dNTPs (1.5 mM), BSA (50 .mu.g/ml). Mixes were boiled
for 5 min and cooled down to room temperature for primer annealing,
3 units/reaction of T4-DNA-Polymerase was then added to a final
volume of 20 .mu.l, and incubated at 37.degree. C., for 30 min for
chain extension. 0.5 .mu.L of each reaction was used as a template
in two PCR reactions: one with template Poly1-T7(+)/Poly-2(-) and
primers PCR-Poly1-F/PCR-Poly2-R and other with template
Poly-3(+)/Poly-4(-) and primers PCR-Poly-3F/PCR-Poly-4R. For both
PCRs, the conditions were: reaction buffer (1.times.), dNTP's (200
.mu.M), forward and reverse primers (0.5 .mu.M/each) and 1 unit of
Taq-DNA-polymerase in a final volume of 20 .mu.l. For each primary
reaction, 3 secondary tubes were prepared and PCR reactions were
performed in gradient for annealing temperature: 94.degree. C., 5
min; 35 cycles of [94.degree. C., 30s; 40.degree. C., 30 s (tube
1); or 45.4.degree. C., 30 s (tube 2); or 50.7.degree. C., 30 s
(tube 3); 72.degree. C., 30 s] and 72.degree. C. 1 min. Bands were
stronger for the 40.degree. C. annealing temperature. The 145 bp
bands were then isolated and digested with enzymes: AflIII and XbaI
for PolyT7/Poly2-R and, AatII and XbaI for Poly3(+)/Poly 4(-).
After inactivating the enzymes at 65.degree. C. 20 min, the
ligation of equimolar amounts of both bands was carried out at
25.degree. C. for 1 h with T.sub.4-DNA-ligase. The 1811 nt
AatII/AflII band of the pUC plasmid was added, and incubated at
16.degree. C. overnight. E. coli Tam1 competent cells were
transformed with the ligations and positively selected colonies
screened by double digestion with AatII and AflIII. The positive
plasmid was named T7-pUC#32 and was checked by sequencing.
[0088] SP6-pUC plasmid. The reaction mix: Poly1-SP6(+) and
Poly-2(-) primers (5 .mu.g each), buffer (1.times.), dNTPs (1.5
mM), BSA(50 .mu.g/ml), was boiled for 5 min and cooled down to rt
for primer annealing. Then 3 units/reaction of T4-DNA-Polymerase
was added to a final volume of 20 .mu.l, and incubated at
37.degree. C., 30 min. 0.5 .mu.l/Rxn was used as a template in a
gradient PCR reaction with PCR-Poly1-F/PCR-Poly2-R primers (0.5
.mu.M/each) reaction buffer (1.times.), dNTP's (200 .mu.M), and 1
unit of Taq-DNA-polymerase in a final volume of 20 .mu.l. PCR
conditions: 94.degree. C., 5 min; 35 cycles of [94.degree. C., 30
s; 40.degree. C., 30 s (tube 4); or 45.4.degree. C., 30 s (tube 5);
or 50.7.degree. C., 30 s (tube 6); 72.degree. C., 30 s] and
72.degree. C. 1 min. Bands were isolated in agarose gels, pooled
together and purified. The DNA obtained was digested with enzymes
AflIII and XbaI for 2 h at 37.degree. C. After inactivating the
enzymes at 65.degree. C., 20 min, the digested DNA band was ligated
to the AatII and XbaI digested Poly-3(+)/Poly-4(-) band at
25.degree. C. for 1 h with T4-DNA-ligase. Five .mu.L of the
ligation was used as the template for a second gradient PCR
reaction carried out with primers PCR-Poly1-F and PCR-Poly4-R,
(same concentrations as previous PCR) and cycles: 94.degree. C. 2
min, 18 cycles of [94.degree. C., 30 s; 40.degree. C., 30 s (tube
4); or 43.1.degree. C., 30 s (tube 5); or 45.4.degree. C., 30 s
(tube 6); 72.degree. C. 30 s] and 72.degree. C. 1 min. Bands were
isolated in an agarose gel, pooled together, purified and
AflIII/AatII digested at 37.degree. C. for 16 h. After enzyme
inactivation (65.degree. C., 20 min), the AflIII/AatII SP6 band was
ligated to the 1811 nt AatII/AflII band of the pUC plasmid with
Quick T4-DNA-ligase (New England Biolabs) at rt for 5 min and
transformed into E. coli Tam1 cells. Screening of colonies was
performed as for T7 polylinker. The plasmid was named
SP6-pUC#51.
[0089] T7-pUC-PolyA#114 plasmid. The Sindbis 3' end from nt 11392
to 11694 was obtained by PCR on plasmid CDNA-5_Topo #525 with
primers: PolyA-F (5' CCCCAATGATCCGACCA 3'') (SEQ ID NO:1) and
PolyA-R (5' AAAACAAATTTTGTTGATTAATAAAAG 3') (SEQ ID NO:2). PCR
conditions: reaction buffer (1.times.), MgSO.sub.4 (1 mM), dNTPs
(0.3 mM each), primers (0.3 .mu.M each) and 1 unit of Platinum Pfx
DNA Polymerase in a final volume of 25 .mu.l. Three PCR reactions
were performed in gradient for annealing temperature: 94.degree.
C., 5 min; 35 cycles of [94.degree. C., 45 s; 53.2.degree. C., 30 s
(tube 1); or 55.5.degree. C., 30 s (tube 2); or 60.8.degree. C., 30
s (tube 3); 72.degree. C. 45 s] and 72.degree. C. 1 min. The
53.2.degree. C. band was stronger and its DNA was isolated from the
gel, phosphorylated with 10 units of T4-Polynucleotide-Kinase
(Biolabs) at 37.degree. C., 30 min. After inactivation at
70.degree. C. 10 min, the DNA was ligated to plasmid T7-pUC#32
(previously digested with HpaI and dephosphorylated) using
T.sub.4-DNA-ligase at 16.degree. C. for 14 h. Screening of
recombinants was performed by PCR of colonies using the same
primers, Taq-Polymerase and cycles: 94.degree. C., 5 min; 35 cycles
of [94.degree. C., 45 s; 53.degree. C., 30 s; 72.degree. C., 45 s]
and 72.degree. C. 1 min. The orientation of the insert was analyzed
with restriction enzymes AflII/AseI. The positive plasmid was
confirmed by sequencing, and named T7-pUC-PolyA#114. From this
vector the final vector T7-ARep#68 and SP6-pUC-PolyA#914 was
generated to construct the final vector SP6-Arep#68.
[0090] Replicon vector constructions. T7-ARep plasmid: Viral cDNA
fragments CDNA-1, CDNA-2, and CDNA-3 were cloned in
T7-pUC-PolyA#114 to generate a new reporter vector T7-ARep#68.
Plasmid CDNA-1_Topo#64 was digested with MfeI and BglII RE and the
2247 bp viral band isolated and ligated, with the quick ligase kit,
to T7-pUC-PolyA#114, MfeI, BglII digested and CIP
dephosphorylated.TAM1 transformant bacteria were screened by PCR
with Taq-Polymerase and primers CDNA-1F and CDNA-1R at: 94.degree.
C. 10 min, 35 cycles of [94.degree. C., 30 s; 65.degree. C., 30 s;
72.degree. C. 2.5 min] and 72.degree. C. 2 min. The positive
plasmid was named T7-pUC-PolyA-C1#11 and was AvrII/BglII digested
and CIP dephosphorylated and ligated, with Quick ligase, to the
CDNA-2 1950 bp viral band, obtained after AvrII/BglII digestion of
plasmid CDNA-2_Topo#213. Screening of positive colonies was made by
PCR with Taq polymerase and primers CDNA-2F and CDNA-2R at:
94.degree. C., 10 min; 35 cycles of [94.degree. C., 30 s;
64.degree. C., 30 s; 72.degree. C. 2.5 m] and 72.degree. C. for 3
min. The plasmid was named T7-pUC-PolyA-C1-C2#35. C3A+B_Topo#810
was digested with XbaI/AvrII and BsshII, the 3350 nt viral C3 band
separated in an agarose gel, isolated and ligated (Quick Ligase
Kit) to XbaI/AvrII digested T7-pUC-PolyA-C1-C2#35 plasmid.
Transformants were analyzed by XbaI/AvrII digestion. The new
reporter vector was named T7-ARep#68, and was fully sequenced.
[0091] SP6-ARep plasmid. The reporter vector under the SP6 promoter
was cloned in three steps. First, the SP6 promoter was cloned into
T7-pUC-PolyA#114, then CDNA-1 was inserted and in the last step,
the CDNA-2+CDNA-3 band from T7-ARep#68 was cloned.
[0092] SP6-pUC#51 was SphI and AflIII digested and the 154 nt band
isolated and ligated (T4-DNA-ligase) to the T7-pUC-PolyA#114
SphI/AflIII/CIP band. Plasmids were screened by MboII digestion and
checked by sequencing. The positive plasmid was named
SP6-pUC-PolyA#902, and was digested with MfeI and BglII, CIP
dephosphorylated and ligated (quick ligase) to the MfeI/BglII
CDNA-1 band. Colonies were analyzed by PCR with CDNA-1F/CDNA-1R
primers at: 94.degree. C. 10 min, 35 cycles of [94.degree. C., 30
s; 65.degree. C., 30 s; 72.degree. C., 2.5 min] and 72.degree. C. 2
min. The positive plasmid was also analyzed by MfeI/BglII digestion
and named SP6-pUC-PolyA-C1#306. Plasmid T7-ARep#68 was BglII/XbaI
digested, and a 5.6 kb CDNA-2+CDNA-3 band was isolated from an
agarose gel and ligated to BglII/XbaI/CIP digested
SP6-pUC-PolyA-C1#306 plasmid. Screening was done by BglII and
BglII/XbaI digestions. The new vector was named SP6-Arep#701.
[0093] Helper vector constructions. T7-AH#17 plasmid. In a first
step Sindbis virus nts 1 to 425 were cloned into T7-pUC-PolyA#114.
In a second step, both CDNA-4 and CDNA-5 viral fragments were
cloned to generate a new helper vector. Sindbis nt 1 to 425 were
amplified by PCR using as a template 54 ng of CDNA-1_Topo#64,
primers (0.5 .mu.M/each) SIN1-19F (5' ATTGACGGCGTAGTACACA 3') (SEQ
ID NO:3) and H-BamR (5' GTATCAAGTAGGATCCGGAG 3') (SEQ ID NO:4)
which adds a BamHI RE to allow CDNA-4 fragment cloning, reaction
buffer (1.times.), dNTP's (200 .mu.M), and 1 unit of
Taq-DNA-polymerase in final volume of 20 .mu.l. Two PCR reactions
were performed in gradient for the following annealing temperature:
94.degree. C. 5 min, 28 cycles of [94.degree. C., 30 s;
45.3.degree. C., 30 s (tube 1); or 46.4.degree. C., 30 s (tube 2);
72.degree. C., 30 s] and 72.degree. C. 1 min. Bands were analyzed
in agarose 1.3% gels, extracted, pooled together and digested with
MfeI/BamHI. Plasmid T7-pUC-PolyA#114 was MfeI/BamHI digested and
CIP dephosphorylated, the band isolated from an agarose gel and
ligated to the 350 bp MfeI/BamHI PCR band. Colonies were screened
by Taq-PCR with primers SIN1-19F/H-BamR at: 94.degree. C., 10 min;
45 cycles of [94.degree. C., 30 s; 45.degree. C., 30 s; 72.degree.
C. 30 s] and 72.degree. C. 1 min. A positive plasmid was checked by
sequencing and named T7-pUC-PolyA-5'#604. This plasmid was digested
with BamHI and NsiI and CIP dephosphorylated to ligate with viral
inserts.
[0094] The ligation of CDNA-4 and CDNA-5 was through RE BclI. This
enzyme is dam methylation dependent, so to demethylate the DNA,
plasmids harboring CDNA-4_Topo#422 and CDNA-5_Topo#525 were
transformed into dam.sup.-/dcm.sup.-1 E. coli strain GM2163 (New
England Biolabs). CDNA-4_Topo#422(dam-) was BamHI and BclI digested
and plasmid CDNA-5_Topo#525 was digested with BclI and NsiI. In
both cases, the enzymes were inactivated at 70.degree. C. for 15
min. The ligation was performed with T4-DNA-Ligase (16.degree. C.
for 14 h) with equimolar amounts of the three bands:
T7-pUC-PolyA-5'#604 (BamHI/NsiI/CIP), CDNA-4_Topo#422(dam.sup.-)
(BamHI/BclI) and CDNA-5_Topo#525(dam.sup.-) (BclI/NsiI). Colonies
were screened by BamHI and NsiI digestion. The positive plasmid was
named T7-AH#17 and was fully sequenced.
[0095] SP6-AH plasmid. Plasmid SP6-pUC-PolyA#902 was digested with
MfeI and NsiI, CIP treated and the 2.4 kb band was ligated
(T4-DNA-ligase) to the 4.5 kb T7-AH#17 MfeI/NsiI band. Colonies
were screened by Taq PCR with primers CDNA-5F and CDNA-5R at:
94.degree. C., 10 min; 25 cycles of [94.degree. C., 30 s;
53.degree. C., 30 s; 72.degree. C. 3 min]. Positive plasmids were
checked by NsiI, and NsiI/MfeI digestions and sequenced. The
resulting plasmid was named SP6-AH#318
[0096] T7-R AND SP6-R plasmids. The four plasmids (SP6-AH#318,
SP6-ARep#701, T7-AH#17 and T7-ARep#68) were fully sequenced, and in
all four, a deletion of one T at the 3' end of the virus before the
polyA, nt 11686 was found. In order to have the same sequence as
the virus Ar-339, the deletion was fixed.
[0097] The Ar-339 sequence was placed first in plasmid
T7-pUC-polyA#114. The new 3' end was obtained by PCR with primers:
PolyA-F (5'CCCCAATGATCCGACCA 3'') (SEQ ID NO:5) and END-R (5'
AAAACAAAATTTTGTTGATTAATAAAAG 3') (SEQ ID NO:6) and cloned into
T7-pUC#32, as described previously for T7-pUC-polyA#114 cloning.
The new plasmid T7-pUC-3end#9 was sequenced and used to generate
new helpers and reporters.
[0098] To generate the reporter vectors, the T7-pUC-3end#9 plasmid
was digested with XbaI and XhoI and the 423 bp band was cloned into
the SP6-Arep#701 XbaI/XhoI 9504 bp band and into the T7-ARep#68
XbaI/XhoI 9504 bp band to generate new reporters SP6-R#406 and
T7-R#202, respectively.
[0099] T7-HAND SP6-H plasmids. Plasmid T7-pUC-3end#9 was digested
with NsiI and XhoI and the 311 bp band was cloned into the
SP6-AH#38 NsiI/XhoI 6399 bp band and into the T7-AH#17 NsiI/XhoI
6399 bp band, to generate, respectively, the new helpers SP6-H#432
and T7-H#226. The new reporters and helper plasmids were fully
sequenced.
[0100] SP6-HE2 mutants. Mutants were made on SP6-H plasmid
following the kit QuickChange IIx site-directed mutagenesis
(Stratagene, La Jolla, Calif.). Briefly, 10 ng of SP6-H#432 were
incubated with complementary primers: E2-I3-F/E2-I3-R or
E2-K70-F/E2-K70-R or E2-E181-F/E2-E181-R or E2-V251-F/E2-V251-R,
reaction buffer, dNTPs and 2.5 units of pfuUltra HF DNA polymerase.
PCR reactions were 95.degree. C. 1 min, 18 cycles of: 95.degree. C.
50 s, 60.degree. C. 50 s, 68.degree. C. 7 min, and final elongation
of 68.degree. C. 7 min.
[0101] After the PCR reactions 10 U of restriction enzyme DpnI was
added and reaction incubated 37.degree. C. 1 hour to digest
methylated parental DNA. XL-10-Gold competent E. coli cells were
transformed and the colonies analyzed by restriction enzyme
digestion (RE). Mutations were verified by sequencing. Multiple
mutants were made following the same protocol using previous
mutants as template for PCR. The sequence of primers used and nt
changes are shown in Table III (Appendix A). Plasmids made:
SP6-H-I3#5; SP6-H-K70#59; SP6-H-I3-K70#66; SP6-H-I3-K70-E181#3;
SP6-H-K70-V251# SP6-H-I3-K70-E181-V251. In order to make sure that
there were not additional mutations due to the PCR technique, the
1270 bp BssHII/BanII fragment of each clone was subcloned in the
sequenced plasmid SP6-H.
[0102] Reporter gene cloning in replicon vectors. The LacZ gene was
cloned in the PmlI/XbaI site of vectors SP6-ARep#701, SP6-R#406,
T7-ARep#68 and T7-R#202 to generate SP6-ARepLacZ, SP6-RLacZ,
T7-ARepLacZ and T7-RLacZ, respectively.
[0103] The firefly luciferase gene was excised at the NheI/XbaI
sites from pGL3 plasmid (Promega Co, Madison Wis.) and cloned in
the XbaI site of vectors: SP6-ARep#701, SP6-R#406, T7-ARep#68 and
T7-R#202 to generate SP6-ARepFluc, SP6-RFluc, T7-ARepFluc and
T7-RFluc, respectively.
[0104] The Renilla luciferase gene from plasmid phRL-CMV (Promega
Co, Madison Wis.) was cloned in the XbaI site of the replicons, to
generate plasmids: SP6-RhRluc and T7-RhRluc.
EXAMPLE 2
[0105] Cells. BHK-21, and ES-2 cells were obtained from the
American Type Culture Collection (ATCC). BHK-21 cells were
maintained in .alpha.MEM (JRH Bioscience) with 5% FBS. ES-2 cells
were derived from a patient with clear cell carcinoma, a type of
ovarian cancer that has a poor prognosis and is resistant to
several chemotherapeutic agents including cisplatin. ES-2 cells
were cultured in McCoy's 5A medium (Mediatech) with 5% FBS. All
basal media were supplemented with 100 .mu.g/ml of
penicillin-streptomycin and 0.5 .mu.g/ml of amphotericin B (both
from Mediatech). ES-2/Fluc cells were derived from the ES-2 line by
transfection of a plasmid, pIRES2-Luc/EGFP, that expresses a
bicistronic mRNA transcript containing both firefly luciferase and
EGFP genes. To construct the pIRES2-Luc/EGFP plasmid, a DNA
fragment containing the luciferase gene was obtained from pGL-3
basic plasmid (Promega) and then subcloned into the multicloning
sites of the pIRES2-EGFP plasmid (BD Biosciences Clontech).
[0106] The mouse ovarian MOSEC cell line (clone ID8) was a generous
gift from Dr. Katherine F. Roby (University of Kansas Medical
Center, Kansas City) and was maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 4% FBS and 1.times.
insulin-transferrin-selenium (Mediatech, Inc).
[0107] In vitro transcription and vector preparation. The plasmids
carrying the Sindbis replicon or JT-BB helper RNAs were linearized
with PacI, NotI or XhoI, before in vitro transcription using the
mMESSAGE mMACHINE RNA transcription kit (T7 and SP6 version;
Ambion). Both helper and replicon RNA transcripts (20 .mu.l each)
were then electroporated into BHK-21 cells and incubated in 10 ml
of .alpha.MEM containing 5% FBS at 37.degree. C. for 12 h. The
medium was replaced with 9 ml of Opti-MEM I medium (GIBCO-BRL,
Invitrogen San Diego Calif.) supplemented with 0.7 .mu.M
CaCl.sub.2. After 24 h, the culture medium was collected and stored
at -80.degree. C.
[0108] Vector titering. The titers of Sindbis vectors were assayed
in BHK-21, ES-2, ES-2/Fluc or MOSEC cells. Serial dilutions (300
.mu.L each) of vector were added to 2.times.10.sup.5 BHK-21 cells
in 12-well plates. After incubation for 1 hour at room temperature,
the cells were washed with PBS and incubated with 2 mL of
.alpha.MEM at 37.degree. C. for 24 hours.
[0109] LacZ expression was determined by two methods: staining and
counting blue cells/well or reading absorbance. For the first,
cells were fixed in PBS containing 0.5% glutaraldehyde at room
temperature for 20 minutes, washed three times with PBS, and then
stained with PBS containing 1 mg/mL X-gal
(5-bromo-4-chloro-3-indolyl-D-galactopyranoside; (Fisher
Scientific, Pittsburgh, Pa.), 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, and 1 mM MgSO4 at 37.degree. C. for 3
hours. After staining with the X-Gal solution, cells that expressed
LacZ were blue. Blue-stained cells were counted and vector titers
were estimated by determining the number of transducing units (TU)
per mL of aliquot. With the second method, cells were lysed with
200/L of M-PER lysis buffer (Pierce Biotechnology, Rockford, Ill.).
50 .mu.L of the cell lysates were added into 50 .mu.L of
All-in-One-Galactosidase Assay Reagent (Pierce Biotechnology) and
incubated at room temperature for 5 minutes before reading at 405
nm. Vector titers were estimated as the last dilution having
detectable absorbance.
[0110] Firefly luciferase activity in cell lysates was determined
by aspirating the culture medium from the wells and adding 200
.mu.L per well of culture medium and 200 .mu.L per well of
Steady-Glo.TM. reagent (Promega Corp., Madison, Wis.). Plates were
incubated with gentle rocking for 5 minutes until the cells
detached from the plates. The cell lysates were then transferred to
12.times.47 mm cuvettes (BD Pharmingen, San Diego, Calif.), and the
luciferase activity of each lysate was determined by taking a
30-second reading with a LUMI-ONE portable luminometer (Bioscan,
Inc., Washington, D.C.).
[0111] Renilla luciferase activity was determined by following the
protocol in "Renilla Luciferase assay system" (Promega Corp.,
Madison, Wis.). Briefly, cells were washed with PBS and 250
.mu.l/well of lysis buffer was added. 20 .mu.L of substrate were
added to 100 .mu.L of extract and the luciferase activity of each
lysate was determined by taking a 30-second reading with a LUMI-ONE
portable luminometer (Bioscan, Inc., Washington, D.C.).
[0112] Animal models. All animal experiments were done in
accordance with NIH and institutional guidelines. To determine the
therapeutic effects of Sindbis virus vectors, SCID mice (female,
6-8 week old; Taconic, Germantown, N.Y.) were i.p. injected with
1.5.times.10.sup.6 ES-2/Fluc cells/mouse on day 0 and imaged with
the IVIS.RTM. system the next day (day 1) to confirm the presence
of tumor cells. Then on day 4, 5 mice/vector received i.p.
treatment with vectors carrying the Renilla luciferase:
A(JT-BB/SP6-RhRluc), B (SP6-H/JT-RephRluc), C(SP6-H/SP6-RhRluc), D
(JT-BB/JT-RephRluc). All vectors had the same titer in ES-2/Fluc
cells, and mice were i.p. injected daily with .about.10.sup.6 TU in
0.5 ml Opti-MEM I/mouse. Control mice (n=5) received no Sindbis
vector treatment. Disease progression was later determined by
IVIS.RTM. imaging on days 1, 5, 9 and 13.
[0113] Survival curves were compared with log rank test. All the P
values presented in this study are two-tailed.
[0114] For colocalization experiments, two SCID mice/vector were
i.p. inoculated with 2.times.10.sup.6 ES-2/Fluc cells on day 0 and
received one i.p. treatment of vector C (.about.10.sup.6 TU in 0.5
mL of OptiMEM I) on day 5. The next day (day 6), mice were i.p.
injected with 0.3 mL of 0.2 mg/mL coelenterazine (Biotium, Inc.,
Hayward, Calif.) followed by IVIS.RTM. imaging for Renilla
luciferase activity. 30 minutes later, the same mice were i.p.
injected with 0.3 mL of 15 mg/mL D-luciferin (Biotium, Inc) and a
second IVIS.RTM. imaging for Firefly luciferase activity was
performed.
[0115] Cell tropism experiments, were done in two groups of SCID
mice with 5 mice/vector: one without tumor induction and the second
one in mice with induced tumors.
[0116] The tumor free animals were i.p. injected with Fluc vectors
on day 0, imaged by IVIS.RTM. on day 1, received a second injection
of vectors on day 2 and on day 3 were IVIS.RTM. imaged again.
[0117] For the second group, SCID female mice were injected i.p. on
day 0 with 2.times.10.sup.6 ES-2 cells/mouse and on day 4 mice were
injected with vectors carrying the luciferase reporter genes. After
the first whole-body IVIS.RTM. imaging on day 1, the peritoneum was
removed for another IVIS.RTM. imaging of the peritoneal cavity. The
remaining mice of the group, except one for background control, had
a second i.p. injection of vectors on day 6 and imaged again on day
7.
[0118] In vivo bioluminescence detection with the IVIS.RTM. Imaging
System. A cryogenically cooled IVIS.RTM. Imaging System Series 100
(Xenogen) was used with Living Image acquisition and analysis
software (Version 2.11, Xenogen Corp. Alameda, Calif.) to detect
the bioluminescence signals in mice. For firefly luciferase
detection, each mouse was injected i.p. with 0.3 ml of 15 mg/ml
beetle luciferin (potassium salt; Promega Corp., Madison, Wis.) in
PBS. After 5 min, mice were anesthetized with 0.3 ml of avertin
(1.25% of 2,2,2-tribromoethanol in 5% tert-amyl alcohol) or
isofluran-mixed oxygen. The imaging system first took a
photographic image in the chamber under dim illumination; this was
followed by luminescent image acquisition. The overlay of the
pseudocolor images represents the spatial distribution of photon
counts produced by active luciferase. An integration time of 1 min
was used for luminescent image acquisition for all mouse tumor
models. Living Image software (Wave Metrics Inc., Lake Oswego,
Oreg.) was used to integrate the total bioluminescence signals (in
terms of proton counts) obtained from mice. The in vitro detection
limit of the IVIS.RTM. Imaging System is 1,000 ES-2/Fluc cells.
[0119] Ar-339 Sequence Analysis
[0120] Ar-339 virus was amplified in chicken embryo fibroblasts and
cloned into sequencing plasmids as six separate overlapping
fragments (FIG. 1). CDNA-3B and CDNA-4 overlap the 312 bp fragment
(nt 7334-7646) that contains the viral subgenomic promoter. In
order to avoid mutations due to RT or PCR reactions, for each
plasmid three different RT reactions were performed and each one
served as template for one PCR reaction. The three PCR amplified
bands of each fragment were cloned separately, sequenced and
compared to verify the virus sequence. The Ar-339 sequence obtained
was compared to the Sindbis published sequence (Strauss E G, Rice C
M and Strauss J H 1984) and to the sequence of Sindbis vectors that
we used previously in our laboratory, JT-BB and JT-Rep. (Tseng et
al 2004a,b). The results are shown in Table IV (Appendix A). The
differences in sequence between the Strauss sequence and JT vectors
are described in Table V (Appendix A). Functional changes between
JT and AR-339 plasmids are summarized in Table VI (Appendix A).
[0121] In the viral replicase, comparing the Strauss map with
Ar-339, three point mutations in nsp1 were found: nt 353 a silent
mutation; nt 1380 and 1381. Both change amino acid 441 from Cys to
Ile in Ar339. In the Sindbis-like virus supergroup, the
methyltransferase nsp1 has four conserved motifs I (a.a 31 to 51),
II (a.a 87 to 86), III (168 to 220) and IV(243 to 260) (Rozanov et
al. 1992). Cys 441 to Ile is not in the carboxyterminal domain
required for enzymatic activity (K468 to L512) (Wang et al. 1996).
Nsp2 has three mutations compared to the Strauss sequence, one
silent at nt 3698 (A to G) and two (nt 2992 and 3579) that change
amino acids 438 (Pro to Leu) and 634 (Lys to Glu) respectively.
Both amino acids are outside the active helicase and protease
domains of nsp2 (Rikkonen et al. 1994). Sindbis virus with Pro at
438, as described in the Strauss sequence, has lethal effects on
virus replication (Rice et al. 1987). In nsp4 there was a silent
mutation at nt 7337 (T to C).
[0122] Regarding the structural proteins, the Ar-339 capsid protein
had two mutations compared with the Strauss sequence, one silent at
nt 8345 (C to A) and one at nt 7846 that changed Pro 67 to Gln. In
the consensus Strauss sequence and JT vectors a Proline occurs at
position 67. This residue is conserved in different isolates of
virus in Australia, and for MK6962, a New Guinea isolate, a Tyr (T)
is present at this site (Sammels et al. 1999). This change is in
the 11 to 74 amino acid region that doesn't bind to Sindbis RNA
(Geigenmuller-Gnirke et al. 1993) and is not in E2 or capsid
proteins interaction domains residues 36-39, 108 to 111, 172, 180
to 183, 201, 231-234, 240 or 254 (Katherine E. Owen and Richard J.
Kuhn, 1996; H. Lee and D. T. Brown 1994).
[0123] There were also two silent mutations in E1 at nt 10392 (T to
C) and 10469 (T to A) and two differences in the Ar-339 with the
Strauss map were found at positions Ala 72 to Val in Ar-339 and 237
(Ser to Ala), which are both located in domain II. Residues of this
domain are involved in E1-E1 interaction in the virus spike (Zhang
W et al. 2002).
[0124] Most of the coding changes were found in the envelope
protein E2, in which the antigenic sites and the binding receptor
domain of the virus have been described. Comparing the Strauss
sequence with Ar-339, five amino acid changes were found located in
the external leaf-like domain of the E2 protein, which extends from
the amino terminus to residue 218 (Zhang W et al. 2002). Changes
are in amino acids: 3 (Ile to Thr); 23 (Val to Ala); 70 (Lys to
Glu) and also two of mutations, 172 (Arg to Gly) and 181 (Glu to
Lys), occur in the putative binding receptor domain (amino acids
170 to 220). No changes were found in the endodomain that interacts
with the capsid protein (from 391 to 483) or with the E2-E1
interaction region.
[0125] An analysis of the amino acid changes between the JT
plasmids and the Ar-339 sequence revealed only one mutation in the
replicase, Cys 441 to Ile of nsp1. In the structural proteins there
were a total of eight differences, only one in the capsid protein,
Pro 67 to Gln; and seven in the E1 and E2 envelope proteins. Three
mutations in E1: Ala 72 to Val; Gly 75 to Asp and Ser 237 to Ala.
Most of the differences were found in the E2 protein, three in the
leaf-Like domain; Ile 3 to Thr; Lys70 to Glu and Glu 181 to Lys and
one in the ectodomain, Val 251 to Ala. V251 is important for virus
maturation in CEF (Li M L et al. 1999).
[0126] Vector Constructions
[0127] To construct the Ar-339 vectors, the Sindbis genome was
split into two plasmids: the replicon and the helper (FIG. 2). This
vector system is designed to electroporate in vitro transcribed
viral RNA into the susceptible cell line to produce replicative
defective Sindbis virus, called viral vector, that contains, as a
genome, the replicase RNA and lacks the structural genes. For in
vitro transcription, a bacteriophage promoter is required before
the viral sequence.
[0128] In order to compare the yield of viral vectors in this
system, two pairs of vectors were produced, one pair with replicon
and helper under the control of the SP6 promoter (SP6-H and SP6-R),
and the other pair under the control of the T7 promoter (T7-H and
T7-R).
[0129] The replicon contains the viral replicase, with the
packaging signal, nt 945 to nt 1075, (Weiss B et al. 1994; Frolova
et al 1997); the viral subgenomic promoter, multicloning site 1
(MCS1) to allow for the insertion and expression of the gene of
interest, and the 3' end of the virus (nt 11394 to 11703) to allow
viral (-) strand RNA synthesis. A second multicloning site (MCS2)
allows the linearization of the plasmid for in vitro
transcription.
[0130] The helper plasmid contains the first 425 nt of the virus,
followed by the 3' end of the virus from nt 7334 to nt 11703 which
includes the subgenomic promoter, the capsid and the viral envelope
proteins (E3, E2, 6K and E1) and the 3' end (nt 11394 to
11703).
[0131] Both plasmids share the following viral sequences: the first
425 nt, the 309 nt of the 3' end and the sub genomic promoter.
[0132] Both plasmids have several non-viral elements in common, the
replication origin (rep pMB1) and the Ampicillin resistance gene
from the pUC cloning plasmid; the promoter for in vitro
transcription (T7 or SP6) and the MCS2. In the construction process
a plasmid containing the pUC sequences, SP6 or T7 promoter, the
multicloning sites, and the 3'viral end, which are common to both
vectors, was first generated. The specific viral sequences were
then cloned into this plasmid (FIG. 3).
[0133] SP6 and T7 Promoters
[0134] For in vitro transcription systems, the RNA yield using SP6
or T7 RNA polymerase for long RNA transcripts could differ. To
study if the promoter would make a difference in the titer of the
viral vectors production, BHK-21 cells were electroporated with two
sets of in vitro transcribed RNAs: SP6-AH and SP6-ARepLacZ, to
generate the SP6-LacZ viral vector, and with T7-AH and T7-ARepLacZ
for the T7-LacZ vector. The comparison of both vector's titers in
BHK-21 cell, in repeated experiments, gave equivalent titers
.apprxeq.10.sup.6 transducing units (TU)/mL. In terms of infective
particles production, both promoters work with the same efficiency
in this system.
[0135] Sequencing of the four plasmids (SP6-AH, SP6-ARep, T7-AH and
T7-ARep) revealed a deletion of one T at the 3' end of the virus
before the poly A (SV nt 11686). To study the effect of this
deletion on viral vectors, four new plasmids without the deletion
were constructed (SP6-H, SP6-R, T7-H and T7-R) and titers of viral
vectors from both sets of plasmids were compared. No significant
difference was observed indicating that the deletion of T11686 is
not critical for vector replication. As these four sets of vectors
showed the same in vitro titer, in order to standardize results the
experiments with mice were performed using SP6-H and SP6-R plasmids
to synthesize viral vectors.
EXAMPLE 3
Biological Properties
[0136] Cell Tropism
[0137] Most of the amino acid differences found between JT and
Ar-339 vectors were in the envelope proteins. One of them was
related to virus adaptation to BHK-21, E2 Lys 70 to Glu (McNight K
et al, 1996) and two of them were located in the receptor-binding
domain of the E2 protein. To analyze if the amino acid changes had
any effect on the viral vector's infectivity, JT, Ar-339 and
chimeric viral vectors were produced and titered in three cell
lines: BHK-21 (baby hamster kidney), ES-2 and Mosec human and mouse
ovarian cancer cell lines respectively. The results are shown in
Table VII (Appendix A). Vectors that carry JT-BB helper
(JT-BB/SP6-ARepLacZ and JT-BB/JT-RepLacZ) had titers two logarithms
higher in BHK-21 than in the other two cell lines; when the helper
was SP6-H, the difference observed was only one log. The
infectivity of the vectors in vitro was similar in both ovarian
cancer cell lines, ES-2 and Mosec. This difference was observed in
repeated experiments.
[0138] Disease Progression
[0139] In order to compare the ability in targeting and suppression
of disease progression by Sindbis vectors Ar-339 and JT, JT and
Ar-339 chimeric vectors were produced and tested in the ES-2/Fluc
mouse metastatic ovarian cancer model described previously (Tseng
et al. 2004b). Five female SCID mice per vector group were injected
i.p. with 1.5.times.10.sup.6 ES-2/Fluc cells (day 0) and IVIS.RTM.
imaged the next day to verify the presence of ES-2/Fluc cells.
Cells were left to grow for four days before daily treatment with
vectors was started. There were five mouse groups, one of which did
not receive vector treatment, whereas the remaining 4 had vectors:
A(JT-BB/SP6-RhRluc), B (SP6-H/JT-RephRluc), C(SP6-H/SP6-RhRluc) and
D (JT-BB/JT-RephRluc). As these strains showed different cell
tropism in BHK-21 cells, vectors were titered in the same cell line
used to induce the tumor ES-2/Fluc, and titers for all vectors were
standardized at 106 TU/mL. Total whole body photon counts were
determined by IVIS.RTM. imaging on days 1, 5, 13, and 19 to
determine disease progression of ES-2/Fluc metastases (FIG. 4).
Survival curves were also compared (FIG. 5).
[0140] Vector A, carrying the Ar-339 replicase (SP6-RhRluc) and JT
structural proteins was more efficient in reducing tumor
progression and gave better survival of the animals. The vectors
carrying the same structural proteins, vector B versus C and A
versus D were compared. In both cases there was more tumor
reduction with Ar-339 replicase (SP6-RhRluc). Regarding the
structural part, when the vectors carrying the same replicase were
analyzed, in one case SP6-H seemed to be more effective (Vectors D
versus B), but in the case of A versus C, where the photon count
difference is larger, JT-BB is more efficient in tumor targeting.
The small differences between vectors B, C and D correlates with
similar animal survival data, although both structural proteins and
replicase function in the efficiency of the vectors in vivo, these
data suggest that an improvement in the targeting of Ar-339
replicase (SP6-R) to tumor cells would lead to more efficient gene
therapy vectors.
[0141] Co-Localization
[0142] To establish the degree and specificity of Ar-339 Sindbis
infection of tumor cells, IVIS.RTM. imaging studies were performed
that measured independent bioluminescent signals from tumor cells
and vectors. The ES-2/Fluc cells expressed the firefly luciferase
gene, that uses D-luciferin as substrate, and the vectors carried a
different luciferase gene cloned from soft coral Renilla renifomis
(Rluc) that uses coelenterazine to generate bioluminescence. The
two luciferases are highly substrate specific and do not
cross-react (Bhaumik S and Gambhir S S. 2002). Each anesthetized
mouse was first treated with coelenterazine the image was collected
(FIG. 6A, left panel), then treated with D-luciferin for a second
IVIS.RTM. imaging, this time of ES-2/Fluc cells (FIG. 6A right
panel). The bioluminescence signals generated in the same animal
from Sindbis/Rluc and ES-2/Fluc, were quantitated using Living
Image software. The images of Rluc and Fluc signals were grided (12
8, 96 boxed regions), and corresponding regions were analyzed for
statistical correlation (FIG. 6B). A highly significant correlation
was established (P<0.0001) indicating that a single i.p.
delivery of Ar-339 Sindbis vector lead to the efficient infection
of the metastasized tumor cells throughout the peritoneal cavity.
In several mice an additional infection outside the peritoneal
cavity was observed.
[0143] Ar-339 Targeting
[0144] To analyze tissues or organs targeted by the Ar-339 strain,
new chimeric vectors were made with firefly luciferase (Fluc) as
the reporter gene, since its stronger bioluminescent signal allows
the study of vectors in animal organs. Each vector was tested in
two groups of 5 SCID female mice: tumor-free and 5 day ES-2
metastasis induced mice. To assess which part of the C vector was
responsible for the chest bioluminiscence, three Fluc chimeric
vectors were made: A(JT-BB/SP6-RFluc), B(SP6-H/JT-RepFluc) and C
(JT-BB/JT-RepFluc). As previously, vectors were titered in ES-2
cells. Tumor free mice received one dose of vector (104 TU/mL) at
day 0 and were IVIS.RTM. imaged next day (FIG. 7A). All three
groups showed a low background signal in fat tissue. Two out of
five vector B mice and one of five mice in vector C group showed
some additional bioluminescent signal in the chest, as previously
observed in the colocalization experiment. To investigate if
vectors were infecting organs in these mice, intraperitoneal cavity
and harvested organs were also IVIS.RTM. imaged. The chest signal
observed corresponded to connective tissue in the ribs, while
organs had no background signal. To study if repeated doses of
these vectors could lead to accumulative infection in tumor-free
mice, a second dose was i.p. injected on day 2 and the image
repeated on day 3. The results (FIG. 7B) showed low background
signal in fat tissue for vectors B and C and no signal at all for
vector A, indicating that the background is transient and shouldn't
affect the target effectiveness of Ar-339 vectors in repeated
treatment.
[0145] Previous studies of JT/Fluc vector in 5 day ES-2 tumor
induced mice, showed that the vector specifically targets
metastasized ES-2 cells after one injection and also in a second
dose two days later (Tseng et al. 2004). To study if the difference
between sequences could affect the specificity of Ar-339 vector,
these 3 chimeric vectors were tested in the same model. Mice
injected with 2.times.10.sup.6 ES-2 cells on day 0, received one
i.p. dose of vectors on day 5 and were IVIS.RTM. imaged on day 6.
The peritoneal cavity and organs of two mice per group were imaged.
As is shown in FIG. 8A for all vectors, bioluminescence correlated
with ES-2 metastatic implants. At day 7 two mice per group received
a second i.p. dose of vector and one mouse was not injected to
serve as a luciferase background signal control (FIG. 8B). Vector A
showed a similar signal compared with previous doses, but vectors
carrying Ar-339 structural proteins, B and C, showed decreased
bioluminescence signals in tumors compared with the first
injection. The difference in reinfection suggests that amino acid
changes in structural proteins could play an important role in
targeting metastases by repetitive treatment with vector.
[0146] In order to determine which mutations were critical for the
vector properties, a chimeric vector was generated, QE2, that
contains E2 from JT-BB and the remaining structural proteins from
Ar-339. When we compared with Ar-339 vector in the same IVIS.RTM.
animal model as in the previous experiment, in tumor free animals,
a low background in fat tissue with the first dose was observed and
no signal in a second dose. In ES-2 5 day induced tumor mice,
vector QE2 targeted tumor and was able to re-infect animals, though
the bioluminescent signal was not as strong as for Ar-339 vector
(data not shown). This indicates that Ar-339 sequence in the E2
envelope protein was primarily responsible for the targeting
pattern, though the optimal amino acid pattern was still not clear.
To address this question site directed mutagenesis was performed on
the Ar-339 E2 envelope protein.
[0147] E2 Mutants
[0148] The E2 envelope has been described as the protein that is
primarily responsible for cell tropism and infectivity of Sindbis
virus. More specifically, Lys 70 is implicated in BHK-21
specificity (McNight K et al, 1996) and also residues 69 to 72 have
been related to targeting vertebrate cells (Ohno K et al. 1997;
Dubuisson J and Rice C M, 1993). As the Ar-339 strain has a Glu in
this position, 3 point mutants were generated that contain Lys at
position 70 (FIG. 9). In Mut-1 only Ar-339 Glu 70 was changed to
Lys. Amino acid 251 of E2 is highly conserved between different
Sindbis isolates (Sammels L M et al. 1999) and mutation to Valine
at this position has been related with host range phenotype (Li M L
et al. 1999). To explore the influence of this amino acid in vector
targeting, Mut-2 was produced that has Lys70 and also Ar-339 Ala
251 mutated to Val. Residues at positions 3 and 181 are located in
the external leaf-like domain of the E2 protein and 181 is in the
receptor binding domain. To assess if the combination of these 4
amino acid changes in the E2 is responsible for the difference in
infection of Ar-339 vectors, mutant Mut-4 was produced with Lys 70,
and Val 251 plus changes in Ar-339 Thr 3 to Ile and Ar-339 Lys 181
to Glu (FIG. 9). The mutants were tested in tumor-free and ES-2 5
day induced tumor mice as previously described for vectors A, B and
C. To assure that the difference in signals were due to the E2
mutations, all five vectors tested carried the same replicase
SP6-RFluc: vector A (JT-BB/SP6-RFluc), C(SP6-H/SP6-RFluc), Mut-1
(SP6-H-K70/SP6-RFluc) Mut-2 (SP6-H-K70-V251/SP6-RFluc) and Mut-4
(SP6-H-I3-K70-E181-V251/SP6-RFluc).
[0149] Vectors were titered in BHK-21 cells and in ovarian cell
lines ES-2 and Mosec (Table VIII (Appendix A)). Mutants showed a
greater difference between A and C when titered in BHK-21 than in
ovarian cell lines.
[0150] In tumor-free mice vectors A and C gave background in some
of the animals. Only one out of the five vector C mice showed a low
bioluminescent signal in the ribs (FIG. 10A). In second doses of
these vectors the background was even less noticeable (FIG. 10B).
Mut-1 and Mut-2 did not produce background bioluminescent signal in
either dose. Mut-4 showed barely detectable signal in fat tissue,
much less intense than vectors A and C.
[0151] In ES-2 tumor induced mice (FIG. 11A) mice #79 in A and #88
in C vector groups did not show bioluminescence; these mice did not
develop ES-2 metastatic implants in the peritoneal cavity (these
mice are not shown in the Figure).
[0152] This result showed a dramatic decrease in the infectivity of
mutants Mut-1 and Mut-2 and an important reduction in Mut-4 after
the first and second dose (FIG. 11). The change of only one amino
acid in Ar-339 E2 at position 70 makes vector C lose the
specificity in targeting ES-2 tumor metastases in vivo. The double
mutant with Valine at position 251, Mut-2, doesn't revert the
vector tropism. Mut-4 combines vector A E2 with Ar-339 E1, E3 and
capsid sequences. The fact that Mut-4 could not revert to fall
infectivity indicates that the interaction between E2 and E1 in the
vector spike could also play an important role in vector
targeting.
EXAMPLE 4
Suppression of Disease Progression by Ar-339, MUT-4 and JT
Vectors
[0153] In previous mouse experiments Vector C showed background
infections in some of the animals treated. Although this effect was
transient and vector C was efficient in suppression of disease
progression, it would be preferable for gene therapy to use a viral
vector that does not cause background tissue infections. In tumor
targeting experiments of SP6-HE2 mutants, vector Mut-4 showed tumor
targeting although with less intensity than vector C (FIG. 11) and
did not show background infection (compare FIGS. 10A and 10B). With
the aim of improving this vector system, the ability of Mut-4 in
tumor reduction was studied and vector-tumor colocalization
analyzed, using the same model described for vectors A, B, C and D
as in previous experiments.
[0154] Materials and Methods
[0155] Animal models. All animal experiments were done in
accordance with NIH and institutional guidelines. To determine the
therapeutic effects of Sindbis virus vectors, SCID mice (female,
6-8 week old; Taconic, Germantown, N.Y.) were i.p. injected with
1.5.times.10.sup.6 ES-2/Fluc cells/mouse on day 0 and imaged with
the IVIS.RTM. system the next day (day 1) to confirm the presence
of tumor cells. Then on day 4, 10 mice/vector received i.p.
treatment with vectors carrying the Renilla luciferase: Mut-4
(SP6-HI3K70E181V251/SP6-RHRluc), C(SP6-H/SP6-RhRluc) and D
(JT-BB/JT-RephRluc). All vectors had the same titer in ES-2/Fluc
cells, and mice were i.p. injected daily with .about.10.sup.6 TU in
0.5 ml Opti-MEM I/mouse. Control mice (n=5) received no Sindbis
vector treatment. Disease progression was later determined by
IVIS.RTM. imaging on days 1, 5, 9 and 13.
[0156] Survival curves were compared with log rank test. All the P
values presented in this study are two-tailed.
[0157] For colocalization experiments, two SCID mice/vector were
i.p. inoculated with 1.5.times.10.sup.6 ES-2/Fluc cells on day 0
and received one i.p. treatment of vector Mut-4 (.about.10.sup.6 TU
in 0.5 mL of OptiMEM I) on day 5. The next day (day 6), mice were
i.p. injected with 0.3 mL of 0.2 mg/mL coelenterazine (Biotium,
Inc., Hayward, Calif.) followed by IVIS.RTM. imaging for Renilla
luciferase activity. 30 minutes later, the same mice were i.p.
injected with 0.3 mL of 15 mg/mL D-luciferin (Biotium, Inc) and a
second IVIS.RTM. imaging for Firefly luciferase activity was
performed.
Results
[0158] Colocalization. To measure the degree and specificity of
Mut-4 Sindbis infection of tumor cells, IVIS.RTM. imaging studies
were performed that measured independent bioluminescent signals
from tumor cells and vector Mut-4 (SP6-HI3K70E181V251/SP6-RhRluc).
The ES-2/Fluc cells expressed the Firefly luciferase gene, that
uses D-luciferin as a substrate, and the vector carried a different
luciferase gene cloned from soft coral Renilla renifomis (hRluc)
that uses coelenterazine to generate bioluminescence. The two
luciferases are highly substrate specific and do not cross-react
(Bhaumik, S, and Gambhir, S. S. 2002). Each anesthetized mouse was
first treated with coelenterazine and the image was collected (FIG.
12A, left panel), then treated with D-luciferin for sequential
IVIS.RTM. imaging of ES-2/Fluc cells (FIG. 12A, right panel). The
bioluminescence signals generated in the same animal from vector
and ES-2/Fluc were quantitated using Living Image software. The
images of Rluc and Fluc signals were grided (12.times.8, 96 boxed
regions), and the corresponding regions were analyzed for
statistical correlation (FIG. 12B). A highly significant
correlation was established (P<0.0001) indicating that a single
i.p. delivery of Mut-4 Sindbis vector leads to very efficient
infection of the metastasized tumor cells throughout the peritoneal
cavity.
[0159] Disease progression. In order to compare the ability of
Sindbis vectors Ar-339 and Mut-4 in targeting and suppression of
disease, vectors were constructed and tested in the ES-2/Fluc mouse
metastatic ovarian cancer model described previously. Ten female
SCID mice per vector group were injected i.p. with
1.5.times.10.sup.6 ES-2/Fluc cells (day 0) and IVIS.RTM. imaged the
next day to verify the presence of ES-2/Fluc cells in the mice.
Cells were left to grow for four days before daily treatment with
vectors was started. There were four groups of animals, one of
which did not receive vector treatment, the remaining 4 were
injected daily with 10.sup.6 TU/ml doses of vectors carrying
Renilla luciferase reporter gene: C(SP6-H/SP6-RhRluc), Mut-4
(SP6-HI3K70E181V251/SP6-RhRluc). and D (JT-BB/JT-RephRluc).
[0160] Total whole body photon counts were determined by IVIS.RTM.
imaging on days 1, 5, 13, and 19 to determine disease progression
of ES-2/Fluc metastases. Survival curves were also compared (FIG.
13). Mice treated with vectors C and Mut-4 showed similar photo
count reduction and survival proportions. These data suggest that
vector Mut-4 (SP6-HI3K70E181V251/SP6-RHRluc) has similar in vivo
efficiency in tumor reduction as vector C(SP6-H/SP6-RhRluc) and so
can also be used in gene therapy. Both vectors, C and Mut-4, showed
significantly improved tumor reduction and mouse survival compared
to vector D.
PAPER EXAMPLE 1
Production of C6/36 Packaging Cell Line with Rederived Ar-339
Plasmids
[0161] Plasmids SP6-H and SP6-R can be used to engineer insect
plasmids to generate a mosquito C6/36-derived packaging cell line
producing Ar-339 Sindbis vectors. Three plasmids with the Opa12
mosquito promoter (described in Theilmann et al., J. Virology,
1995, 69(12):7775-7781) are required to constitutively express
viral sequences in mosquito cells. The replicon plasmid
(pIZ-Ar339-R) will have the replicase, subgenomic promoter and gene
of interest and the other two will contain the split helper
sequences, one with capsid protein only (PIB-Ar339-C) and the
second one with E1, E2, E3 and K6 envelope proteins (pIZ-Ar339-H).
In a first step the C6/36 cell line (available from the American
Type Culture Collection, ATCC, Manassas, Va. as ATCC CRL 1660) will
be transfected with replicon plasmid (pIZ-Ar339-R) and clones will
be selected. In a second step the previous clones containing the
replicon will be transfected with the capsid plasmid (PIB-Ar339-C)
and replicon and capsid positive clones selected. In the last step,
the 2.sup.nd helper plasmid (pIZ-Ar339-H) will be transfected into
the previously isolated clones to generate the packaging cell line
that express all three plasmids.
[0162] 1.--Cloning of SP6-R Replicase into PIZ/V5-HIS Plasmid
[0163] In order to clone the Ar-339 replicase in PIZ/V5-His
(Invitrogen, San Diego, Calif.) it is necessary to introduce a SacI
RE site before the SP6 promoter.
[0164] 1.1--PCR Reactions will be performed on SP6-R#406 plasmid
using primers SacI_SP6F/cDNA-1R, and then the 2340 bp band will be
cloned in pcr4blunt_topo vector (Invitrogen, San Diego, Calif.).
The new plasmids TOPO-Rep1
TABLE-US-00001 Primer sequences: SacI_SP6F GGCTAGAGCTCATTTAGGTGACA
(SacI) cDNA-1R GTAACAAGATCTCGTGCCGTGACA
[0165] 1.2.--The SP6-R#406 plasmid will be digested with BglII/NotI
and cloned the 5776 bp band into BglII/NotI TOPO-Rep1 to make new
plasmid TOPO-Ar339-R
[0166] 1.3.--The 8085 bp SacI/NotI TOPO-Ar339-R band will be cloned
into SacI/NotI PIZ/V5-His to generate pIZ-Ar339-R.
[0167] 2.--Cloning OF Ar-339 Helper P
[0168] In order to minimize the presence of recombinant replicative
competent virus, the helper genome will be split into two plasmids:
PIB-Ar339-C and pIZ-Ar339-H.
[0169] 2.1 Construction of pIB-Ar339-C
[0170] The Ar-339 Capsid DNA sequence will be cloned into
pIB-V5-His (Invitrogen, San Diego, Calif.) at the BamHI/SpeI site
of the vector. PCR will be performed on plasmid SP6-H#432 using
primers C1-F and C1-R to obtain the Ar-339 capsid 1133 bp DNA
band.
TABLE-US-00002 C1-F GGA TCT CCG GAT CCC CTG AAA AGG (BamHI) C1-R
GTG ACC AGT GGA CTA GTG GAC CAC TCT TC (SpeI)
[0171] The band will be digested and cloned into the pIB-V5-His
vector at the BamHI/SpeI site to make the new plasmid
pIB-Ar-339-C.
[0172] 2.2 Construction of pIZ-Ar339-H
[0173] The first step is to clone the 5' end of Ar-339 (from nt 425
to 692) into pIZ/V5-His. PCR reactions will be performed on SP6#432
plasmid with primers 416B-F and 676NB-R. Restriction sites will be
included in this no coding sequence to allow further cloning of
helper sequence.
TABLE-US-00003 416B-F GGA TCT CCG GAT CCC CTG AAA AGG CTG T (BamHI)
676NB-R GAT GAA AGG ATC CTC GCG AAC TAT TTA GGA CCA CCG
(BamHI/NruI)
[0174] The 296 bp band will be digested with BamHI and cloned in
the BamHI site of pIZ/V5-His to make pIZ-5END plasmid.
[0175] In a second step SP6-H#432 plasmid will be digested with
NruI and XhoI and the 3435 bp band will be cloned into the
NruI/XhoI site of the pIZ-5END plasmid.
REFERENCES
[0176] Bhaumik S, Gambhir S S. Optical imaging of Renilla
luciferase reporter gene expression in living mice. Proc Natl Acad
Sci USA 2002; 99:377-82. [0177] Burge B W, Pfefferkom E R.
"Complementation between temperature-sensitive mutants of Sindbis
virus". Virology. 1966 October; 30(2):214-23. [0178] Dubuisson J,
Rice C M. "Sindbis virus attachment: isolation and characterization
of mutants with impaired binding to vertebrate cells." J Virol.
1993 June; 67(6):3363-74. [0179] Frolova E, Frolov I, Schlesinger
S. "Packaging signals in alphaviruses." J Virol. 1997 January;
71(1):248-58. [0180] Frothingham (1955). "Tissue culture applied to
the study of Sindbis virus." Am. J. Trop. Med. Hyg. 4: 863-871.
[0181] Geigenmuller-Gnirke U, Nitschko H, Schlesinger S. "Deletion
analysis of the capsid protein of Sindbis virus: identification of
the RNA binding region." J Virol. 1993 March; 67(3):1620-6. [0182]
Hurlbut, H. S. (1953). "The experimental transmission of
coxsackie-like viruses by mosquitoes." J. Egypt. Med. Assoc. 36:
495-498. [0183] Lee H, Brown D T. "Mutations in an exposed domain
of Sindbis virus capsid protein result in the production of
noninfectious virions and morphological variants." Virology. 1994
July; 202(1):390-400. [0184] Levy-Mintz P, Kielian M. "Mutagenesis
of the putative fusion domain of the Semliki Forest virus spike
protein." J Virol. 1991 August; 65(8):4292-300. [0185] Li M L, Liao
H J, Simon L D, Stollar V. "An amino acid change in the exodomain
of the E2 protein of Sindbis virus, which impairs the release of
virus from chicken cells but not from mosquito cells." Virology.
1999 Nov. 10; 264(1):187-94. [0186] McKnight K L, Simpson D A, Lin
S C, Knott T A, Polo J M, Pence D F, Johannsen D B, Heidner H W,
Davis N L, Johnston R E. "Deduced consensus sequence of Sindbis
virus strain AR339: mutations contained in laboratory strains which
affect cell culture and in vivo phenotypes." J Virol. 1996 March;
70(3):1981-9. [0187] Myles K M, Pierro D J, Olson K E. "Deletions
in the putative cell receptor-binding domain of Sindbis virus
strain MRE16 E2 glycoprotein reduce midgut infectivity in Aedes
aegypti." J Virol. 2003 August; 77(16):8872-81. [0188] Ohno K,
Sawai K, Iijima Y, Levin B, Meruelo D. "Cell-specific targeting of
Sindbis virus vectors displaying IgG-binding domains of protein A".
Nat Biotechnol. 1997 August; 15(8):763-7. [0189] Owen K. E. and
Kuhn. R. J. "Identification of a region in the Sindbis virus
nucleocapsid protein that is involved in specificity of RNA
encapsidation". J. of Virology, May 1996, p 2757-2763. [0190] Rice
C M, Levis R, Strauss J H, Huang H V "Production of infectious RNA
transcripts from Sindbis virus cDNA clones: mapping of lethal
mutations, rescue of a temperature-sensitive marker, and in vitro
mutagenesis to generate defined mutants." J Virol. 1987 December;
61(12):3809-19. [0191] Rikkonen M, Peranen J, Kaariainen L. "ATPase
and GTPase activities associated with Semliki Forest virus
nonstructural protein nsP2." J Virol. 1994 September;
68(9):5804-10. [0192] Rozanov M N, Koonin E V, Gorbalenya A E.
"Conservation of the putative methyltransferase domain: a hallmark
of the `Sindbis-like` supergroup of positive-strand RNA viruses." J
Gen Virol. 1992 August; 73 (Pt 8):2129-34. [0193] Sammels L M,
Lindsay M D, Poidinger M, Coelen R J, Mackenzie J S. "Geographic
distribution and evolution of Sindbis virus in Australia." J Gen
Virol. 1999 March; 80 (Pt 3):739-48. [0194] Strauss E G, Rice C M,
Strauss J H. "Complete nucleotide sequence of the genomic RNA of
Sindbis virus." Virology. 1984 February; 133(1):92-110. [0195]
Strauss, J. H. and Strauss, E. G. "The alphaviruses: gene
expression, replication, and evolution" Microbiol Rev. 1994
September; 58(3): 491-562. [0196] Taylor, R M and H S Hurlbut
(1953). "Isolation of coxsackie-like viruses from mosquitoes." J.
Egypt. Med. Assoc. 36: 489-494. [0197] Taylor, R M, H S Hurlbut, T
H Work, J R Kingsbury and T E Frothingham (1955). "Sindbis virus: A
newly recognized arthropod-transmitted virus." Am. J. Trop. Med.
Hyg. 4: 844-846. [0198] Tseng J C, Levin B, Hirano T, Yee H,
Pampeno C, Meruelo D. In vivo antitumor activity of sindbis viral
vectors. J Natl Cancer Inst (Bethesda) 2002; 94: 1790-802. [0199]
Tseng J C, Levin B, Hurtado A, et al. Systemic tumor targeting and
killing by Sindbis viral vectors. Nat Biotechnol 2004a; 22:70-7.
[0200] Tseng J C, Hurtado A, Yee H, Levin B, Boivin C, Benet M,
Blank S V, Pellicer A, Meruelo D. "Using sindbis viral vectors for
specific detection and suppression of advanced ovarian cancer in
animal models." Cancer Res. 2004b Sep. 15; 64(18):6684-92. [0201]
Wang H L, O'Rear J, Stollar V. "Mutagenesis of the Sindbis virus
nsP1 protein: effects on methyltransferase activity and viral
infectivity." Virology. 1996 Mar. 15; 217(2):527-31. [0202] Weiss
B, Geigenmuller-Gnirke U, Schlesinger S. "Interactions between
Sindbis virus RNAs and a 68 amino acid derivative of the viral
capsid protein further defines the capsid binding site." Nucleic
Acids Res. 1994 Mar. 11; 22(5):780-6. [0203] Zhang W, Mukhopadhyay
S, Pletnev S V, Baker T S, Kuhn R J, Rossmann M G "Placement of the
structural proteins in Sindbis virus." J Virol. 2002 November;
76(22):11645-58.
[0204] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from the
foregoing description and the accompanying figures. Such
modifications are intended to fall within the scope of the appended
claims.
[0205] It is further to be understood that all values are
approximate, and are provided for description.
[0206] Patents, patent applications, publications, product
descriptions, and protocols are cited throughout this application,
the disclosures of which are incorporated herein by reference in
their entireties for all purposes.
TABLE-US-00004 TABLE I APPENDIX A Primers used for Sindbis cDNA
cloning. PRIMER SEQUENCE (5' .fwdarw. 3') SV NT cDNA bp cDNA-1F
ATTGACGGCGTAGTACAC (SEQ ID NO:7) 1-20 cDNA-1 cDNA-1R
GTAACAAGATCTCGTGCCGTGACA (Bgl II) (SEQ ID NO:8) 2299-2276 2276 bp
cDNA-2F GGCACGAGATCTTGTTACCAGC (Bgl II) (SEQ ID NO:9) 2281-2303
cDNA-2 cDNA-2R CTTTCTTTCCTAGGCACACAGTCATTCTT (Avr II) (SEQ ID
NO:10) 4265-4293 2012 bp cDNA-3F GACTGTGTGCCTAGGAAAGAAAGTG (Avr II)
(SEQ ID NO:11) 4271-4295 cDNA-3A SV-6932R CACACCCAGGTCCTCCAAGATC
(SEQ ID NO:12) 6932-6953 2682 bp SV-6882F GCATCATTCGACAAAAGCCAAG
(SEQ ID NO:13) 6882-6903 cDNA-3B SV-C3R
CTCTTCTAGAGGTGGTGGTGTTGTAGTATT (XbaI) (SEQ ID NO:14) 7626-7656 774
bp cDNA-4F GGATCCCCTGAAAAGGCTGTTTAAG (BamHI) (SEQ ID NO:15)
7334-7359 cDNA-4 cDNA-4R TCATGTCTGATCAAGTCCGGTGA (BclI) (SEQ ID
NO:16) 9370-9348 2014 bp cDNA-5F GGACTTGATCAGACATGACGACCA (BclI)
(SEQ ID NO:17) 9353-9376 CDNA-5 cDNA-5R
TTTTTGAAATGTTAAAAACAAAATTTTGTTG (SEQ ID NO:18) 11678-11703 2350 bp
The restriction endonuclease recognition sites are underlined.
Sindbis virus nucleotide numbers follow Strauss et al (1984)
sequence (Accession# NC_001547.1)
TABLE-US-00005 TABLE II Primers used to generate vector
polylinkers. PRIMER (RE) SEQUENCE 5'.fwdarw. 3' Poly1-T7(+)
CCCACATGTGGGAGGCTAGAGTACTTAATACGACTCACTATAGGATTGACGGCGTAGTACACACTATTGAATC-
AAACAGCCGACC (AflIII) (SEQ ID NO:19) Poly1-
CCCACATGTGGGAGGCTAGAGTACATTTAGGTGACACTATAGAAATTGACGGCGTAGTACACACTAT-
TGAATCAAACAGCCGACC SP6(+) (SEQ ID NO:20) (AflIII) Poly-2(-)
GGCGCGCCTCTAGACTAGCCTAGGTATGGAAGATCTTCCGCGGATCCGCCTAGTGCAATTGGTC-
GGCTGTTTGATTCAAT (XbaI) (SEQ ID NO:21) Poly-3(+)
AGGCTAGTCTAGAGGCGCGCCGATCTCACGTGAGCATGCGTTTAAACTGGGCCCAATGTTAACA-
TTTCAAAAAAAAAAAAAAAAA XbaI) (SEQ ID NO:22) Poly-4(-)
GGTGATGACGTCCTCGAGGCGGCCGCTTAATTAATTTAAATTTTTTTTTTTTTTTTTTTTTTTT-
TTTTTTTTTTTTTTGAAATGT (AatII) (SEQ ID NO:23) PCRPoly-1F
ATATATATCCCACATGT (AflIII) (SEQ ID NO:24) PCRPoly-2R GCGCGCCTCTAGA
(SEQ ID NO:25) PCRPoly-3F AGGCTAGTCTAGAGGC (SEQ ID NO:26)
PCRPoly-4R GGTGATGACGTCCT (AatII) (SEQ ID NO:27) Restriction
endonuclease recognition sites (RE) are underlined. Overlapping
sequences are shown in bold.
TABLE-US-00006 TABLE III PRIMERS USED IN SITE-DIRECTED MUTAGENESIS
OF E2 GENE. PRIMER SEQUENCE 5'.fwdarw. 3' RE E2-I3-F
GCAAAAGAAGCGTCATCGATGACTTTACCCTGA ClaI CCAGC (SEQ ID NO:28) E2-I3-R
GCTGGTCAGGGTAAAGTCATCGATGACGCTTCT ClaI TTTGC (SEQ ID NO:29)
E2-K70-F CTACATGTCGCTTAAGCAGGATCACACCGTTAA Afl II AG (SEQ ID NO:30)
E2-K70-R CTTTAACGGTGTGATCCTGCTTAAGCGACATGT Afl II AG (SEQ ID NO:31)
E2-E181-F CGGGCCCGCACGCTTATACATCCTACCTGGAAG Sma I AATCATC (SEQ ID
NO:32) E2-E181-R GATGATTCTTCCAGGTAGGATGTATAAGCGTGC Sma I GGGCCCG
(SEQ ID NO:33) E2-V251-F GACTTGATCCGACATGACGACCACACGGTCCAA Mme I
GGG (SEQ ID NO:34) E2-V251-R CCCTTGGACCGTGTGGTCGTCATGTCGGATCAA Mme
I GTC (SEQ ID NO:35) Nucleotides changed are underlined and the new
restriction sites generated are indicated (RE)
TABLE-US-00007 TABLE IV Nucleotide differences between Ar-339, JT
vectors and Sindbis virus Strauss sequence (Strauss et al. 1984)
Protein Codon Codon Codon nt (a.a.) JT Strauss Ar-339 Strauss
.quadrature. Ar339 Strauss .quadrature. JT JT .quadrature. Ar339
353 nsP1(98) C C T UAC(Tyr)_UAU(Tyr) UAC(Tyr)_UAC(Tyr)
UAC(Tyr)_UAU(Tyr) 1380-1 nsP1(441) TG TG AT UGC(Cys)_AUC(Ile)
UGC(Cys)_UGC(Cys) UGC(Cys)_AUC(Ile) 2992 nsP2(438) T C T
CCC(Pro)_CUC(Leu) CCC(Pro)_CUC(Leu) CUC(Leu)_CUC(Leu) 3579
nsP2(634) G A G AAA(Lys)_GAA(Glu) AAA(Lys)_GAA(Glu)
GAA(Glu)_GAA(Glu) 3698 nsP2(673) A G G AAG(Lys) AAG(Lys) AAG(Lys)
AAA(Lys) AAA(Lys)_AAG(Lys) 5702 nsP3(534) T A A CCA(Pro)_CCA(Pro)
CCA(Pro)_CCU(Pro) CCU(Pro)_CCA(Pro) 7337 nsP4(529) T T C
GAU(Asp)_GAC(Asp) GAU(Asp)_GAC(Asp) GAU(Asp)_GAC(Asp) 7846 C(67) C
C A CCG(Pro)_CAG(Gln) CCG(Pro)_CCG(Pro) CCG(Pro)_CAG(Gln) 8009
C(121) A G G GAG(Glu)_GAG(Glu) GAG(Glu)_GAA(Glu) GAA(Glu)_GAG(Glu)
8345 C(233) C C A GGC(Gly)_GGA(Gly) GGC(Gly)_GGC(Gly)
GGC(Gly)_GGA(Gly) 8638 E2(3) T T C AUU(Ile)_ACU(Thr)
AUU(Ile)_AUU(Ile) AUU(Ile)_ACU(Thr) 8698 E2(23) A T A
GUA(Val)_GCA(Ala) GUA(Val)_GCA(Ala) GCA(Ala)_GCA(Ala) 8838 E2(70) A
A G AAG(Lys)_GAG(Glu) AAG(Lys)_AAG(Lys) AAG(Lys)_GAG(Glu) 9144
E2(172) G A G AGA(Arg)_GGA(Gly) AGA(Arg).quadrature.GGA(Gly)
GGA(Gly)_GGA(Gly) 9171 E2(181) G G A GAA(Glu)_AAA(Lys)
GAA(Glu)_GAA(Glu) GAA(Glu)_AAA(Lys) 9382 E2(251) T C C
GCC(Ala)_GCC(Ala) GCC(Ala)_GUC(Val) GUC(Val)_GCC(Ala) 10279 E1(72)
C C T GCU(Ala)_GUU(Val) GCU(Ala)_GCU(Ala) GCU(Ala)_GUU(Val) 10288
E1(75) G A A GAC(Asp)_GAC(Asp) GAC(Asp)_GGC(Gly) GGC(Gly)_GAC(Asp)
10392 E1(109) T T C UUG(Leu)_CUG(Leu) UUG(Leu)_UUG(Leu)
UUG(Leu)_CUG(Leu) 10469 E1(133) T T A AUU(Ile)_AUA(Ile)
AUU(Ile)_AUU(Ile) AUU(Ile)_AUA(Ile) 10773 E1(237) T T G
UCA(Ser)_GCA(Ala) UCA(Ser)_UCA(Ser) UCA(Ser)_GCA(Ala) Nucleotide
numbers follow the Strauss et al sequence. (Accession#
NC_001547.1)
TABLE-US-00008 TABLE V Nucleotide differences between JT vectors
and Strauss sequence Protein Codon nt (a.a.) Strauss .quadrature.
JT Plasmid 2992 nsP2(438) CCC(Pro)_CUC(Leu) Replicon 3579 nsP2(634)
AAA(Lys)_GAA(Glu) Replicon 3698 nsP2(673) AAG(Lys) AAA(Lys)
Replicon 5702 nsP3(534) CCA(Pro)_CCU(Pro) Replicon 7337 nsP4(529)
GAU(Asp)_GAC(Asp) Replicon 8009 Capsid(121) GAG(Glu)_GAA(Glu)
Helper 8698 E2(23) GUA(Val)_GCA(Ala) Helper 9144 E2(172)
AGA(Arg)_GGA(Gly) Helper 9382 E2(251) GCC(Ala)_GUC(Val) Helper
10288 E1(75) GAC(Asp)_GGC(Gly) Helper Strauss et al 1984 sequence.
(Accession# NC_001547.1)
TABLE-US-00009 TABLE VI Summary of amino acid differences between
JT and Ar-339 vectors Protein Codon nt (a.a.) JT.quadrature. Ar339
Plasmid 1380/1381 nsP1(441) UGC(Cys)_AUC(Ile) Replicon 7846
Capsid(67) CCG(Pro)_CAG(Gln) Helper 8638 E2(3) AUU(Ile)_ACU(Thr)
Helper 8838 E2(70) AAG(Lys)_GAG(Glu) Helper 9171 E2(181)
GAA(Glu)_AAA(Lys) Helper 9382 E2(251) GUC(Val)_GCC(Ala) Helper
10279 E1(72) GCU(Ala)_GUU(Val) Helper 10288 E1(75)
GGC(Gly)_GAC(Asp) Helper 10773 E1(153) UCA(Ser)_GCA(Ala) Helper
TABLE-US-00010 TABLE VII TITER OF CHIMERIC VIRAL VECTORS. BHK-21
cells ES-2/Fluc cells Mosec cells VIRAL VECTOR (TU/mL) (TU/mL)
(TU/mL) JT-BB/SP6-ARepLacZ 3 .times. 10.sup.6 3 .times. 10.sup.4 3
.times. 10.sup.4 SP6-AH/JT-RepLacZ 3 .times. 10.sup.4 3 .times.
10.sup.3 3 .times. 10.sup.3 SP6-AH/SP6-ARepLacZ 3 .times. 10.sup.4
3 .times. 10.sup.3 3 .times. 10.sup.3 JT-BB/JT-RepLacZ 3 .times.
10.sup.6 3 .times. 10.sup.4 3 .times. 10.sup.4 Vectors were titered
in BHK-21, ES-2/Fluc and Mosec cell lines. TU transducing units
TABLE-US-00011 TABLE VIII TITERS OF E2 MUTANT VECTORS. BHK-21
ES-2/Fluc Mosec VIRAL VECTOR (TU/mL) (TU/mL) (TU/mL) A
(JT-BB/SP6-RFluc) 10.sup.7 10.sup.5 10.sup.6 C (SP6-H/SP6-RFluc)
10.sup.5 10.sup.3 10.sup.4 Mut-1 (SP6H-K70/SP6- 10.sup.4 10.sup.3
10.sup.5 RFluc) Mut-2 (SP6H-K70-V251/ 10.sup.5 10.sup.4 10.sup.2
SP6-RFluc) Mut-4 (SP6H-I3-K70- 10.sup.6 10.sup.4 10.sup.5
E181-V251/SP6-RFluc) Vectors were titered in BHK-21, ES-2/Fluc and
Mosec cell lines. TU transducing units
Sequence CWU 1
1
40117DNAartificialprimer 1ccccaatgat ccgacca
17227DNAartificialprimer 2aaaacaaatt ttgttgatta ataaaag
27319DNAartificialprimer 3attgacggcg tagtacaca
19420DNAartificialprimer 4gtatcaagta ggatccggag
20517DNAartificialprimer 5ccccaatgat ccgacca
17628DNAartificialprimer 6aaaacaaaat tttgttgatt aataaaag
28718DNAartificialprimer 7attgacggcg tagtacac
18824DNAartificialprimer 8gtaacaagat ctcgtgccgt gaca
24922DNAartificialprimer 9ggcacgagat cttgttacca gc
221029DNAartificialprimer 10ctttctttcc taggcacaca gtcattctt
291125DNAartificialprimer 11gactgtgtgc ctaggaaaga aagtg
251222DNAartificialprimer 12cacacccagg tcctccaaga tc
221322DNAartificialprimer 13gcatcattcg acaaaagcca ag
221430DNAartificialprimer 14ctcttctaga ggtggtggtg ttgtagtatt
301525DNAartificialprimer 15ggatcccctg aaaaggctgt ttaag
251623DNAartificialprimer 16tcatgtctga tcaagtccgg tga
231724DNAartificialprimer 17ggacttgatc agacatgacg acca
241831DNAartificialprimer 18tttttgaaat gttaaaaaca aaattttgtt g
311985DNAartificialprimer 19cccacatgtg ggaggctaga gtacttaata
cgactcacta taggattgac ggcgtagtac 60acactattga atcaaacagc cgacc
852085DNAartificialprimer 20cccacatgtg ggaggctaga gtacatttag
gtgacactat agaaattgac ggcgtagtac 60acactattga atcaaacagc cgacc
852180DNAartificialprimer 21ggcgcgcctc tagactagcc taggtatgga
agatcttccg cggatccgcc tagtgcaatt 60ggtcggctgt ttgattcaat
802285DNAartificialprimer 22aggctagtct agaggcgcgc cgatctcacg
tgagcatgcg tttaaactgg gcccaatgtt 60aacatttcaa aaaaaaaaaa aaaaa
852385DNAartificialprimer 23ggtgatgacg tcctcgaggc ggccgcttaa
ttaatttaaa tttttttttt tttttttttt 60tttttttttt ttttttttga aatgt
852417DNAartificialprimer 24atatatatcc cacatgt
172513DNAartificialprimer 25gcgcgcctct aga
132616DNAartificialprimer 26aggctagtct agaggc
162714DNAartificialprimer 27ggtgatgacg tcct
142838DNAartificialprimer 28gcaaaagaag cgtcatcgat gactttaccc
tgaccagc 382938DNAartificialprimer 29gctggtcagg gtaaagtcat
cgatgacgct tcttttgc 383035DNAartificialprimer 30ctacatgtcg
cttaagcagg atcacaccgt taaag 353135DNAartificialprimer 31ctttaacggt
gtgatcctgc ttaagcgaca tgtag 353240DNAartificialprimer 32cgggcccgca
cgcttataca tcctacctgg aagaatcatc 403340DNAartificialprimer
33gatgattctt ccaggtagga tgtataagcg tgcgggcccg
403436DNAartificialprimer 34gacttgatcc gacatgacga ccacacggtc caaggg
363536DNAartificialprimer 35cccttggacc gtgtggtcgt catgtcggat caagtc
36369928DNASindbis virus 36attgacggcg tagtacacac tattgaatca
aacagccgac caattgcact accatcacaa 60tggagaagcc agtagtaaac gtagacgtag
acccccagag tccgtttgtc gtgcaactgc 120aaaaaagctt cccgcaattt
gaggtagtag cacagcaggt cactccaaat gaccatgcta 180atgccagagc
attttcgcat ctggccagta aactaatcga gctggaggtt cctaccacag
240cgacgatctt ggacataggc agcgcaccgg ctcgtagaat gttttccgag
caccagtatc 300attgtgtctg ccccatgcgt agtccagaag acccggaccg
catgatgaaa tatgccagta 360aactggcgga aaaagcgtgc aagattacaa
acaagaactt gcatgagaag attaaggatc 420tccggaccgt acttgatacg
ccggatgctg aaacaccatc gctctgcttt cacaacgatg 480ttacctgcaa
catgcgtgcc gaatattccg tcatgcagga cgtgtatatc aacgctcccg
540gaactatcta tcatcaggct atgaaaggcg tgcggaccct gtactggatt
ggcttcgaca 600ccacccagtt catgttctcg gctatggcag gttcgtaccc
tgcgtacaac accaactggg 660ccgacgagaa agtccttgaa gcgcgtaaca
tcggactttg cagcacaaag ctgagtgaag 720gtaggacagg aaaattgtcg
ataatgagga agaaggagtt gaagcccggg tcgcgggttt 780atttctccgt
aggatcgaca ctttatccag aacacagagc cagcttgcag agctggcatc
840ttccatcggt gttccacttg aatggaaagc agtcgtacac ttgccgctgt
gatacagtgg 900tgagttgcga aggctacgta gtgaagaaaa tcaccatcag
tcccgggatc acgggagaaa 960ccgtgggata cgcggttaca cacaatagcg
agggcttctt gctatgcaaa gttactgaca 1020cagtaaaagg agaacgggta
tcgttccctg tgtgcacgta catcccggcc accatatgcg 1080atcagatgac
tggtataatg gccacggata tatcacctga cgatgcacaa aaacttctgg
1140ttgggctcaa ccagcgaatt gtcattaacg gtaggactaa caggaacacc
aacaccatgc 1200aaaattacct tctgccgatc atagcacaag ggttcagcaa
atgggctaag gagcgcaagg 1260atgatcttga taacgagaaa atgctgggta
ctagagaacg caagcttacg tatggctgct 1320tgtgggcgtt tcgcactaag
aaagtacatt cgttttatcg cccacctgga acgcagacca 1380tcgtaaaagt
cccagcctct tttagcgctt ttcccatgtc gtccgtatgg acgacctctt
1440tgcccatgtc gctgaggcag aaattgaaac tggcattgca accaaagaag
gaggaaaaac 1500tgctgcaggt ctcggaggaa ttagtcatgg aggccaaggc
tgcttttgag gatgctcagg 1560aggaagccag agcggagaag ctccgagaag
cacttccacc attagtggca gacaaaggca 1620tcgaggcagc cgcagaagtt
gtctgcgaag tggaggggct ccaggcggac atcggagcag 1680cattagttga
aaccccgcgc ggtcacgtaa ggataatacc tcaagcaaat gaccgtatga
1740tcggacagta tatcgttgtc tcgccaaact ctgtgctgaa gaatgccaaa
ctcgcaccag 1800cgcacccgct agcagatcag gttaagatca taacacactc
cggaagatca ggaaggtacg 1860cggtcgaacc atacgacgct aaagtactga
tgccagcagg aggtgccgta ccatggccag 1920aattcctagc actgagtgag
agcgccacgt tagtgtacaa cgaaagagag tttgtgaacc 1980gcaaactata
ccacattgcc atgcatggcc ccgccaagaa tacagaagag gagcagtaca
2040aggttacaaa ggcagagctt gcagaaacag agtacgtgtt tgacgtggac
aagaagcgtt 2100gcgttaagaa ggaagaagcc tcaggtctgg tcctctcggg
agaactgacc aaccctccct 2160atcatgagct agctctggag ggactgaaga
cccgacctgc ggtcccgtac aaggtcgaaa 2220caataggagt gataggcaca
ccggggtcgg gcaagtcagc tattatcaag tcaactgtca 2280cggcacgaga
tcttgttacc agcggaaaga aagaaaattg tcgcgaaatt gaggccgacg
2340tgctaagact gaggggtatg cagattacgt cgaagacagt agattcggtt
atgctcaacg 2400gatgccacaa agccgtagaa gtgctgtacg ttgacgaagc
gttcgcgtgc cacgcaggag 2460cactacttgc cttgattgct atcgtcaggc
cccgcaagaa ggtagtacta tgcggagacc 2520ccatgcaatg cggattcttc
aacatgatgc aactaaaggt acatttcaat caccctgaaa 2580aagacatatg
caccaagaca ttctacaagt atatctcccg gcgttgcaca cagccagtta
2640cagctattgt atcgacactg cattacgatg gaaagatgaa aaccacgaac
ccgtgcaaga 2700agaacattga aatcgatatt acaggggcca caaagccgaa
gccaggggat atcatcctga 2760catgtttccg cgggtgggtt aagcaattgc
aaatcgacta tcccggacat gaagtaatga 2820cagccgcggc ctcacaaggg
ctaaccagaa aaggagtgta tgccgtccgg caaaaagtca 2880atgaaaaccc
actgtacgcg atcacatcag agcatgtgaa cgtgttgctc acccgcactg
2940aggacaggct agtgtggaaa accttgcagg gcgacccatg gattaagcag
ctcactaaca 3000tacctaaagg aaactttcag gctactatag aggactggga
agctgaacac aagggaataa 3060ttgctgcaat aaacagcccc actccccgtg
ccaatccgtt cagctgcaag accaacgttt 3120gctgggcgaa agcattggaa
ccgatactag ccacggccgg tatcgtactt accggttgcc 3180agtggagcga
actgttccca cagtttgcgg atgacaaacc acattcggcc atttacgcct
3240tagacgtaat ttgcattaag tttttcggca tggacttgac aagcggactg
ttttctaaac 3300agagcatccc actaacgtac catcccgccg attcagcgag
gccggtagct cattgggaca 3360acagcccagg aacccgcaag tatgggtacg
atcacgccat tgccgccgaa ctctcccgta 3420gatttccggt gttccagcta
gctgggaagg gcacacaact tgatttgcag acggggagaa 3480ccagagttat
ctctgcacag cataacctgg tcccggtgaa ccgcaatctt cctcacgcct
3540tagtccccga gtacaaggag aagcaacccg gcccggtcga aaaattcttg
aaccagttca 3600aacaccactc agtacttgtg gtatcagagg aaaaaattga
agctccccgt aagagaatcg 3660aatggatcgc cccgattggc atagccggtg
cagataagaa ctacaacctg gctttcgggt 3720ttccgccgca ggcacggtac
gacctggtgt tcatcaacat tggaactaaa tacagaaacc 3780accactttca
gcagtgcgaa gaccatgcgg cgaccttaaa aaccctttcg cgttcggccc
3840tgaattgcct taacccagga ggcaccctcg tggtgaagtc ctatggctac
gccgaccgca 3900acagtgagga cgtagtcacc gctcttgcca gaaagtttgt
cagggtgtct gcagcgagac 3960cagattgtgt ctcaagcaat acagaaatgt
acctgatttt ccgacaacta gacaacagcc 4020gtacacggca attcaccccg
caccatctga attgcgtgat ttcgtccgtg tatgagggta 4080caagagatgg
agttggagcc gcgccgtcat accgcaccaa aagggagaat attgctgact
4140gtcaagagga agcagttgtc aacgcagcca atccgctggg tagaccaggc
gaaggagtct 4200gccgtgccat ctataaacgt tggccgacca gttttaccga
ttcagccacg gagacaggca 4260ccgcaagaat gactgtgtgc ctaggaaaga
aagtgatcca cgcggtcggc cctgatttcc 4320ggaagcaccc agaagcagaa
gccttgaaat tgctacaaaa cgcctaccat gcagtggcag 4380acttagtaaa
tgaacataac atcaagtctg tcgccattcc actgctatct acaggcattt
4440acgcagccgg aaaagaccgc cttgaagtat cacttaactg cttgacaacc
gcgctagaca 4500gaactgacgc ggacgtaacc atctattgcc tggataagaa
gtggaaggaa agaatcgacg 4560cggcactcca acttaaggag tctgtaacag
agctgaagga tgaagatatg gagatcgacg 4620atgagttagt atggatccat
ccagacagtt gcttgaaggg aagaaaggga ttcagtacta 4680caaaaggaaa
attgtattcg tacttcgaag gcaccaaatt ccatcaagca gcaaaagaca
4740tggcggagat aaaggtcctg ttccctaatg accaggaaag taatgaacaa
ctgtgtgcct 4800acatattggg tgagaccatg gaagcaatcc gcgaaaagtg
cccggtcgac cataacccgt 4860cgtctagccc gcccaaaacg ttgccgtgcc
tttgcatgta tgccatgacg ccagaaaggg 4920tccacagact tagaagcaat
aacgtcaaag aagttacagt atgctcctcc accccccttc 4980ctaagcacaa
aattaagaat gttcagaagg ttcagtgcac gaaagtagtc ctgtttaatc
5040cgcacactcc cgcattcgtt cccgcccgta agtacataga agtgccagaa
cagcctaccg 5100ctcctcctgc acaggccgag gaggcccccg aagttgtagc
gacaccgtca ccatctacag 5160ctgataacac ctcgcttgat gtcacagaca
tctcactgga tatggatgac agtagcgaag 5220gctcactttt ttcgagcttt
agcggatcgg acaactctat tactagtatg gacagttggt 5280cgtcaggacc
tagttcacta gagatagtag accgaaggca ggtggtggtg gctgacgttc
5340atgccgtcca agagcctgcc cctattccac cgccaaggct aaagaagatg
gcccgcctgg 5400cagcggcaag aaaagagccc actccaccgg caagcaatag
ctctgagtcc ctccacctct 5460cttttggtgg ggtatccatg tccctcggat
caattttcga cggagagacg gcccgccagg 5520cagcggtaca acccctggca
acaggcccca cggatgtgcc tatgtctttc ggatcgtttt 5580ccgacggaga
gattgatgag ctgagccgca gagtaactga gtccgaaccc gtcctgtttg
5640gatcatttga accgggcgaa gtgaactcaa ttatatcgtc ccgatcagcc
gtatcttttc 5700cactacgcaa gcagagacgt agacgcagga gcaggaggac
tgaatactga ctaaccgggg 5760taggtgggta catattttcg acggacacag
gccctgggca cttgcaaaag aagtccgttc 5820tgcagaacca gcttacagaa
ccgaccttgg agcgcaatgt cctggaaaga attcatgccc 5880cggtgctcga
cacgtcgaaa gaggaacaac tcaaactcag gtaccagatg atgcccaccg
5940aagccaacaa aagtaggtac cagtctcgta aagtagaaaa tcagaaagcc
ataaccactg 6000agcgactact gtcaggacta cgactgtata actctgccac
agatcagcca gaatgctata 6060agatcaccta tccgaaacca ttgtactcca
gtagcgtacc ggcgaactac tccgatccac 6120agttcgctgt agctgtctgt
aacaactatc tgcatgagaa ctatccgaca gtagcatctt 6180atcagattac
tgacgagtac gatgcttact tggatatggt agacgggaca gtcgcctgcc
6240tggatactgc aaccttctgc cccgctaagc ttagaagtta cccgaaaaaa
catgagtata 6300gagccccgaa tatccgcagt gcggttccat cagcgatgca
gaacacgcta caaaatgtgc 6360tcattgccgc aactaaaaga aattgcaacg
tcacgcagat gcgtgaactg ccaacactgg 6420actcagcgac attcaatgtc
gaatgctttc gaaaatatgc atgtaatgac gagtattggg 6480aggagttcgc
tcggaagcca attaggatta ccactgagtt tgtcaccgca tatgtagcta
6540gactgaaagg ccctaaggcc gccgcactat ttgcaaagac gtataatttg
gtcccattgc 6600aagaagtgcc tatggataga ttcgtcatgg acatgaaaag
agacgtgaaa gttacaccag 6660gcacgaaaca cacagaagaa agaccgaaag
tacaagtgat acaagccgca gaacccctgg 6720cgactgctta cttatgcggg
attcaccggg aattagtgcg taggcttacg gccgtcttgc 6780ttccaaacat
tcacacgctt tttgacatgt cggcggagga ttttgatgca atcatagcag
6840aacacttcaa gcaaggcgac ccggtactgg agacggatat cgcatcattc
gacaaaagcc 6900aagacgacgc tatggcgtta accggtctga tgatcttgga
ggacctgggt gtggatcaac 6960cactactcga cttgatcgag tgcgcctttg
gagaaatatc atccacccat ctacctacgg 7020gtactcgttt taaattcggg
gcgatgatga aatccggaat gttcctcaca ctttttgtca 7080acacagtttt
gaatgtcgtt atcgccagca gagtactaga agagcggctt aaaacgtcca
7140gatgtgcagc gttcattggc gacgacaaca tcatacatgg agtagtatct
gacaaagaaa 7200tggctgagag gtgcgccacc tggctcaaca tggaggttaa
gatcatcgac gcagtcatcg 7260gtgagagacc accttacttc tgcggcggat
ttatcttgca agattcggtt acttccacag 7320cgtgccgcgt ggcggacccc
ctgaaaaggc tgtttaagtt gggtaaaccg ctcccagccg 7380acgacgagca
agacgaagac agaagacgcg ctctgctaga tgaaacaaag gcgtggttta
7440gagtaggtat aacaggcact ttagcagtgg ccgtgacgac ccggtatgag
gtagacaata 7500ttacacctgt cctactggca ttgagaactt ttgcccagag
caaaagagca ttccaagcca 7560tcagagggga aataaagcat ctctacggtg
gtcctaaata gtcagcatag tacatttcat 7620ctgactaata ctacaacacc
accacctcta gaggcgcgcc gatctcacgt gagcatgcgt 7680ttaaactggg
cccaatgttc cccaatgatc cgaccagcaa aactcgatgt acttccgagg
7740aactgatgtg cataatgcat caggctggta cattagatcc ccgcttaccg
cgggcaatat 7800agcaacacta aaaactcgat gtacttccga ggaagcgcag
tgcataatgc tgcgcagtgt 7860tgccacataa ccactatatt aaccatttat
ctagcggacg ccaaaaactc aatgtatttc 7920tgaggaagcg tggtgcataa
tgccacgcag cgtctgcata acttttatta tttcttttat 7980taatcaacaa
aattttgttt ttaacatttc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
8040aaaaaaaatt taaattaatt aagcggccgc ctcgaggacg tcaggtggca
cttttcgggg 8100aaatgtgcgc ggaaccccta tttgtttatt tttctaaata
cattcaaata tgtatccgct 8160catgagacaa taaccctgat aaatgcttca
ataatattga aaaaggaaga gtatgagtat 8220tcaacatttc cgtgtcgccc
ttattccctt ttttgcggca ttttgccttc ctgtttttgc 8280tcacccagaa
acgctggtga aagtaaaaga tgctgaagat cagttgggtg cacgagtggg
8340ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc
ccgaagaacg 8400ttttccaatg atgagcactt ttaaagttct gctatgtggc
gcggtattat cccgtattga 8460cgccgggcaa gagcaactcg gtcgccgcat
acactattct cagaatgact tggttgagta 8520ctcaccagtc acagaaaagc
atcttacgga tggcatgaca gtaagagaat tatgcagtgc 8580tgccataacc
atgagtgata acactgcggc caacttactt ctgacaacga tcggaggacc
8640gaaggagcta accgcttttt tgcacaacat gggggatcat gtaactcgcc
ttgatcgttg 8700ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt
gacaccacga tgcctgtagc 8760aatggcaaca acgttgcgca aactattaac
tggcgaacta cttactctag cttcccggca 8820acaattaata gactggatgg
aggcggataa agttgcagga ccacttctgc gctcggccct 8880tccggctggc
tggtttattg ctgataaatc tggagccggt gagcgtgggt ctcgcggtat
8940cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct
acacgacggg 9000gagtcaggca actatggatg aacgaaatag acagatcgct
gagataggtg cctcactgat 9060taagcattgg taactgtcag accaagttta
ctcatatata ctttagattg atttaaaact 9120tcatttttaa tttaaaagga
tctaggtgaa gatccttttt gataatctca tgaccaaaat 9180cccttaacgt
gagttttcgt tccactgagc gtcagacccc gtagaaaaga tcaaaggatc
9240ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa
aaccaccgct 9300accagcggtg gtttgtttgc cggatcaaga gctaccaact
ctttttccga aggtaactgg 9360cttcagcaga gcgcagatac caaatactgg
tcttctagtg tagccgtagt taggccacca 9420cttcaagaac tctgtagcac
cgcctacata cctcgctctg ctaatcctgt taccagtggc 9480tgctgccagt
ggcgataagt cgtgtcttac cgggttggac tcaagacgat agttaccgga
9540taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca cagcccagct
tggagcgaac 9600gacctacacc gaactgagat acctacagcg tgagctatga
gaaagcgcca cgcttcccga 9660agggagaaag gcggacaggt atccggtaag
cggcagggtc ggaacaggag agcgcacgag 9720ggagcttcca gggggaaacg
cctggtatct ttatagtcct gtcgggtttc gccacctctg 9780acttgagcgt
cgatttttgt gatgctcgtc aggggggcgg agcctatgga aaaacgccag
9840caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca
tgtgggaggc 9900tagagtacat ttaggtgaca ctatagaa 9928376711DNASindbis
virus 37attgacggcg tagtacacac tattgaatca aacagccgac caattgcact
accatcacaa 60tggagaagcc agtagtaaac gtagacgtag acccccagag tccgtttgtc
gtgcaactgc 120aaaaaagctt cccgcaattt gaggtagtag cacagcaggt
cactccaaat gaccatgcta 180atgccagagc attttcgcat ctggccagta
aactaatcga gctggaggtt cctaccacag 240cgacgatctt ggacataggc
agcgcaccgg ctcgtagaat gttttccgag caccagtatc 300attgtgtctg
ccccatgcgt agtccagaag acccggaccg catgatgaaa tatgccagta
360aactggcgga aaaagcgtgc aagattacaa acaagaactt gcatgagaag
attaaggatc 420tccggatccc ctgaaaaggc tgtttaagtt gggtaaaccg
ctcccagccg acgacgagca 480agacgaagac agaagacgcg ctctgctaga
tgaaacaaag gcgtggttta gagtaggtat 540aacaggcact ttagcagtgg
ccgtgacgac ccggtatgag gtagacaata ttacacctgt 600cctactggca
ttgagaactt ttgcccagag caaaagagca ttccaagcca tcagagggga
660aataaagcat ctctacggtg gtcctaaata gtcagcatag tacatttcat
ctgactaata 720ctacaacacc accaccatga atagaggatt ctttaacatg
ctcggccgcc gccccttccc 780ggcccccact gccatgtgga ggccgcggag
aaggaggcag gcggccccga tgcctgcccg 840caacgggctg gcttctcaaa
tccagcaact gaccacagcc gtcagtgccc tagtcattgg 900acaggcaact
agacctcaac ccccacgtcc acgccagcca ccgcgccaga agaagcaggc
960gcccaagcaa ccaccgaagc cgaagaaacc aaaaacgcag gagaagaaga
agaagcaacc 1020tgcaaaaccc aaacccggaa agagacagcg catggcactt
aagttggagg ccgacagatt 1080gttcgacgtc aagaacgagg acggagatgt
catcgggcac gcactggcca tggaaggaaa 1140ggtaatgaaa cctctgcacg
tgaaaggaac catcgaccac cctgtgctat caaagctcaa 1200atttaccaag
tcgtcagcat acgacatgga gttcgcacag ttgccagtca acatgagaag
1260tgaggcattc acctacacca gtgaacaccc cgaaggattc tataactggc
accacggagc 1320ggtgcagtat agtggaggta gatttaccat ccctcgcgga
gtaggaggca gaggagacag 1380cggtcgtccg atcatggata actccggtcg
ggttgtcgcg atagtcctcg gtggagctga 1440tgaaggaaca cgaactgccc
tttcggtcgt cacctggaat agtaaaggga agacaattaa 1500gacgaccccg
gaagggacag aagagtggtc cgcagcacca ctggtcacgg caatgtgttt
1560gctcggaaat gtgagcttcc catgcgaccg cccgcccaca tgctataccc
gcgaaccttc 1620cagagccctc gacatccttg aagagaacgt gaaccatgag
gcctacgata ccctgctcaa 1680tgccatattg cggtgcggat cgtctggcag
aagcaaaaga agcgtcactg acgactttac 1740cctgaccagc ccctacttgg
gcacatgctc gtactgccac catactgaac cgtgcttcag 1800ccctgttaag
atcgagcagg tctgggacga agcggacgat aacaccatac gcatacagac
1860ttccgcccag tttggatacg accaaagcgg agcagcaagc gcaaacaagt
accgctacat 1920gtcgcttgag caggatcaca ccgttaaaga aggcaccatg
gatgacatca agattagcac 1980ctcaggaccg tgtagaaggc ttagctacaa
aggatacttt ctcctcgcaa aatgccctcc 2040aggggacagc gtaacggtta
gcatagtgag tagcaactca gcaacgtcat gtacactggc 2100ccgcaagata
aaaccaaaat tcgtgggacg ggaaaaatat gatctacctc ccgttcacgg
2160taaaaaaatt ccttgcacag tgtacgaccg tctgaaagaa acaactgcag
gctacatcac 2220tatgcacagg ccgggaccgc acgcttatac atcctacctg
aaagaatcat cagggaaagt 2280ttacgcaaag ccgccatctg ggaagaacat
tacgtatgag tgcaagtgcg gcgactacaa 2340gaccggaacc gtttcgaccc
gcaccgaaat cactggttgc accgccatca agcagtgcgt 2400cgcctataag
agcgaccaaa cgaagtgggt cttcaactca ccggacttga tcagacatga
2460cgaccacacg gcccaaggga aattgcattt gcctttcaag ttgatcccga
gtacctgcat 2520ggtccctgtt gcccacgcgc cgaatgtaat acatggcttt
aaacacatca gcctccaatt 2580agatacagac cacttgacat tgctcaccac
caggagacta ggggcaaacc cggaaccaac 2640cactgaatgg atcgtcggaa
agacggtcag aaacttcacc gtcgaccgag atggcctgga 2700atacatatgg
ggaaatcatg agccagtgag ggtctatgcc caagagtcag caccaggaga
2760ccctcacgga tggccacacg aaatagtaca gcattactac catcgccatc
ctgtgtacac 2820catcttagcc gtcgcatcag ctaccgtggc gatgatgatt
ggcgtaactg ttgcagtgtt 2880atgtgcctgt aaagcgcgcc gtgagtgcct
gacgccatac gccctggccc caaacgccgt 2940aatcccaact tcgctggcac
tcttgtgctg cgttaggtcg gccaatgctg aaacgttcac 3000cgagaccatg
agttacttgt ggtcgaacag tcagccgttc ttctgggtcc agttgtgcat
3060acctttggcc gctttcatcg ttctaatgcg ctgctgctcc tgctgcctgc
cttttttagt 3120ggttgccggc gcctacctgg cgaaggtaga cgcctacgaa
catgcgacca ctgttccaaa 3180tgtgccacag ataccgtata aggcacttgt
tgaaagggca gggtatgccc cgctcaattt 3240ggagatcact gtcatgtcct
cggaggtttt gccttccacc aaccaagagt acattacctg 3300caaattcacc
actgtggtcc cctccccaaa aatcaaatgc tgcggctcct tggaatgtca
3360gccggccgtt catgcagact atacctgcaa ggtcttcgga ggggtctacc
cctttatgtg 3420gggaggagcg caatgttttt gcgacagtga gaacagccag
atgagtgagg cgtacgtcga 3480actgtcagca gattgcgcgt ctgaccacgc
gcaggcgatt aaggtgcaca ctgccgcgat 3540gaaagtagga ctgcgtatag
tgtacgggaa cactaccagt ttcctagatg tgtacgtgaa 3600cggagtcaca
ccaggaacgt ctaaagactt gaaagtcata gctggaccaa tttcagcatc
3660gtttacgcca ttcgatcata aggtcgttat ccatcgcggc ctggtgtaca
actatgactt 3720cccggaatat ggagcgatga aaccaggagc gtttggagac
attcaagcta cctccttgac 3780tagcaaggat ctcatcgcca gcacagacat
taggctactc aagccttccg ccaagaacgt 3840gcatgtcccg tacacgcagg
ccgcatcagg atttgagatg tggaaaaaca actcaggccg 3900cccactgcag
gaaaccgcac ctttcgggtg taagattgca gtaaatccgc tccgagcggt
3960ggactgttca tacgggaaca ttcccatttc tattgacatc ccgaacgctg
cctttatcag 4020gacatcagat gcaccactgg tctcaacagt caaatgtgaa
gtcagtgagt gcacttattc 4080agcagacttc ggcgggatgg ccaccctgca
gtatgtatcc gaccgcgaag gtcaatgccc 4140cgtacattcg cattcgagca
cagcaactct ccaagagtcg acagtacatg tcctggagaa 4200aggagcggtg
acagtacact ttagcaccgc gagtccacag gcgaacttta tcgtatcgct
4260gtgtgggaag aagacaacat gcaatgcaga atgtaaacca ccagctgacc
atatcgtgag 4320caccccgcac aaaaatgacc aagaatttca agccgccatc
tcaaaaacat catggagttg 4380gctgtttgcc cttttcggcg gcgcctcgtc
gctattaatt ataggactta tgatttttgc 4440ttgcagcatg atgctgacta
gcacacgaag atgaccgcta cgccccaatg atccgaccag 4500caaaactcga
tgtacttccg aggaactgat gtgcataatg catcaggctg gtacattaga
4560tccccgctta ccgcgggcaa tatagcaaca ctaaaaactc gatgtacttc
cgaggaagcg 4620cagtgcataa tgctgcgcag tgttgccaca taaccactat
attaaccatt tatctagcgg 4680acgccaaaaa ctcaatgtat ttctgaggaa
gcgtggtgca taatgccacg cagcgtctgc 4740ataactttta ttatttcttt
tattaatcaa caaaattttg tttttaacat ttcaaaaaaa 4800aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa atttaaatta attaagcggc cgcctcgagg
4860acgtcaggtg gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt
atttttctaa 4920atacattcaa atatgtatcc gctcatgaga caataaccct
gataaatgct tcaataatat 4980tgaaaaagga agagtatgag tattcaacat
ttccgtgtcg cccttattcc cttttttgcg 5040gcattttgcc ttcctgtttt
tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa 5100gatcagttgg
gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt
5160gagagttttc gccccgaaga acgttttcca atgatgagca cttttaaagt
tctgctatgt 5220ggcgcggtat tatcccgtat tgacgccggg caagagcaac
tcggtcgccg catacactat 5280tctcagaatg acttggttga gtactcacca
gtcacagaaa agcatcttac ggatggcatg 5340acagtaagag aattatgcag
tgctgccata accatgagtg ataacactgc ggccaactta 5400cttctgacaa
cgatcggagg accgaaggag ctaaccgctt ttttgcacaa catgggggat
5460catgtaactc gccttgatcg ttgggaaccg gagctgaatg aagccatacc
aaacgacgag 5520cgtgacacca cgatgcctgt agcaatggca acaacgttgc
gcaaactatt aactggcgaa 5580ctacttactc tagcttcccg gcaacaatta
atagactgga tggaggcgga taaagttgca 5640ggaccacttc tgcgctcggc
ccttccggct ggctggttta ttgctgataa atctggagcc 5700ggtgagcgtg
ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgt
5760atcgtagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa
tagacagatc 5820gctgagatag gtgcctcact gattaagcat tggtaactgt
cagaccaagt ttactcatat 5880atactttaga ttgatttaaa acttcatttt
taatttaaaa ggatctaggt gaagatcctt 5940tttgataatc tcatgaccaa
aatcccttaa cgtgagtttt cgttccactg agcgtcagac 6000cccgtagaaa
agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc
6060ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca
agagctacca 6120actctttttc cgaaggtaac tggcttcagc agagcgcaga
taccaaatac tgtccttcta 6180gtgtagccgt agttaggcca ccacttcaag
aactctgtag caccgcctac atacctcgct 6240ctgctaatcc tgttaccagt
ggctgctgcc agtggcgata agtcgtgtct taccgggttg 6300gactcaagac
gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc
6360acacagccca gcttggagcg aacgacctac accgaactga gatacctaca
gcgtgagcta 6420tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca
ggtatccggt aagcggcagg 6480gtcggaacag gagagcgcac gagggagctt
ccagggggaa acgcctggta tctttatagt 6540cctgtcgggt ttcgccacct
ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg 6600cggagcctat
ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg
6660ccttttgctc acatgtggga ggctagagta catttaggtg acactataga a
6711386711DNASindbis virus 38attgacggcg tagtacacac tattgaatca
aacagccgac caattgcact accatcacaa 60tggagaagcc agtagtaaac gtagacgtag
acccccagag tccgtttgtc gtgcaactgc 120aaaaaagctt cccgcaattt
gaggtagtag cacagcaggt cactccaaat gaccatgcta 180atgccagagc
attttcgcat ctggccagta aactaatcga gctggaggtt cctaccacag
240cgacgatctt ggacataggc agcgcaccgg ctcgtagaat gttttccgag
caccagtatc 300attgtgtctg ccccatgcgt agtccagaag acccggaccg
catgatgaaa tatgccagta 360aactggcgga aaaagcgtgc aagattacaa
acaagaactt gcatgagaag attaaggatc 420tccggatccc ctgaaaaggc
tgtttaagtt gggtaaaccg ctcccagccg acgacgagca 480agacgaagac
agaagacgcg ctctgctaga tgaaacaaag gcgtggttta gagtaggtat
540aacaggcact ttagcagtgg ccgtgacgac ccggtatgag gtagacaata
ttacacctgt 600cctactggca ttgagaactt ttgcccagag caaaagagca
ttccaagcca tcagagggga 660aataaagcat ctctacggtg gtcctaaata
gtcagcatag tacatttcat ctgactaata 720ctacaacacc accaccatga
atagaggatt ctttaacatg ctcggccgcc gccccttccc 780ggcccccact
gccatgtgga ggccgcggag aaggaggcag gcggccccga tgcctgcccg
840caacgggctg gcttctcaaa tccagcaact gaccacagcc gtcagtgccc
tagtcattgg 900acaggcaact agacctcaac ccccacgtcc acgccagcca
ccgcgccaga agaagcaggc 960gcccaagcaa ccaccgaagc cgaagaaacc
aaaaacgcag gagaagaaga agaagcaacc 1020tgcaaaaccc aaacccggaa
agagacagcg catggcactt aagttggagg ccgacagatt 1080gttcgacgtc
aagaacgagg acggagatgt catcgggcac gcactggcca tggaaggaaa
1140ggtaatgaaa cctctgcacg tgaaaggaac catcgaccac cctgtgctat
caaagctcaa 1200atttaccaag tcgtcagcat acgacatgga gttcgcacag
ttgccagtca acatgagaag 1260tgaggcattc acctacacca gtgaacaccc
cgaaggattc tataactggc accacggagc 1320ggtgcagtat agtggaggta
gatttaccat ccctcgcgga gtaggaggca gaggagacag 1380cggtcgtccg
atcatggata actccggtcg ggttgtcgcg atagtcctcg gtggagctga
1440tgaaggaaca cgaactgccc tttcggtcgt cacctggaat agtaaaggga
agacaattaa 1500gacgaccccg gaagggacag aagagtggtc cgcagcacca
ctggtcacgg caatgtgttt 1560gctcggaaat gtgagcttcc catgcgaccg
cccgcccaca tgctataccc gcgaaccttc 1620cagagccctc gacatccttg
aagagaacgt gaaccatgag gcctacgata ccctgctcaa 1680tgccatattg
cggtgcggat cgtctggcag aagcaaaaga agcgtcactg acgactttac
1740cctgaccagc ccctacttgg gcacatgctc gtactgccac catactgaac
cgtgcttcag 1800ccctgttaag atcgagcagg tctgggacga agcggacgat
aacaccatac gcatacagac 1860ttccgcccag tttggatacg accaaagcgg
agcagcaagc gcaaacaagt accgctacat 1920gtcgcttaag caggatcaca
ccgttaaaga aggcaccatg gatgacatca agattagcac 1980ctcaggaccg
tgtagaaggc ttagctacaa aggatacttt ctcctcgcaa aatgccctcc
2040aggggacagc gtaacggtta gcatagtgag tagcaactca gcaacgtcat
gtacactggc 2100ccgcaagata aaaccaaaat tcgtgggacg ggaaaaatat
gatctacctc ccgttcacgg 2160taaaaaaatt ccttgcacag tgtacgaccg
tctgaaagaa acaactgcag gctacatcac 2220tatgcacagg ccgggaccgc
acgcttatac atcctacctg aaagaatcat cagggaaagt 2280ttacgcaaag
ccgccatctg ggaagaacat tacgtatgag tgcaagtgcg gcgactacaa
2340gaccggaacc gtttcgaccc gcaccgaaat cactggttgc accgccatca
agcagtgcgt 2400cgcctataag agcgaccaaa cgaagtgggt cttcaactca
ccggacttga tcagacatga 2460cgaccacacg gcccaaggga aattgcattt
gcctttcaag ttgatcccga gtacctgcat 2520ggtccctgtt gcccacgcgc
cgaatgtaat acatggcttt aaacacatca gcctccaatt 2580agatacagac
cacttgacat tgctcaccac caggagacta ggggcaaacc cggaaccaac
2640cactgaatgg atcgtcggaa agacggtcag aaacttcacc gtcgaccgag
atggcctgga 2700atacatatgg ggaaatcatg agccagtgag ggtctatgcc
caagagtcag caccaggaga 2760ccctcacgga tggccacacg aaatagtaca
gcattactac catcgccatc ctgtgtacac 2820catcttagcc gtcgcatcag
ctaccgtggc gatgatgatt ggcgtaactg ttgcagtgtt 2880atgtgcctgt
aaagcgcgcc gtgagtgcct gacgccatac gccctggccc caaacgccgt
2940aatcccaact tcgctggcac tcttgtgctg cgttaggtcg gccaatgctg
aaacgttcac 3000cgagaccatg agttacttgt ggtcgaacag tcagccgttc
ttctgggtcc agttgtgcat 3060acctttggcc gctttcatcg ttctaatgcg
ctgctgctcc tgctgcctgc cttttttagt 3120ggttgccggc gcctacctgg
cgaaggtaga cgcctacgaa catgcgacca ctgttccaaa 3180tgtgccacag
ataccgtata aggcacttgt tgaaagggca gggtatgccc cgctcaattt
3240ggagatcact gtcatgtcct cggaggtttt gccttccacc aaccaagagt
acattacctg 3300caaattcacc actgtggtcc cctccccaaa aatcaaatgc
tgcggctcct tggaatgtca 3360gccggccgtt catgcagact atacctgcaa
ggtcttcgga ggggtctacc cctttatgtg 3420gggaggagcg caatgttttt
gcgacagtga gaacagccag atgagtgagg cgtacgtcga 3480actgtcagca
gattgcgcgt ctgaccacgc gcaggcgatt aaggtgcaca ctgccgcgat
3540gaaagtagga ctgcgtatag tgtacgggaa cactaccagt ttcctagatg
tgtacgtgaa 3600cggagtcaca ccaggaacgt ctaaagactt gaaagtcata
gctggaccaa tttcagcatc 3660gtttacgcca ttcgatcata aggtcgttat
ccatcgcggc ctggtgtaca actatgactt 3720cccggaatat ggagcgatga
aaccaggagc gtttggagac attcaagcta cctccttgac 3780tagcaaggat
ctcatcgcca gcacagacat taggctactc aagccttccg ccaagaacgt
3840gcatgtcccg tacacgcagg ccgcatcagg atttgagatg tggaaaaaca
actcaggccg 3900cccactgcag gaaaccgcac ctttcgggtg taagattgca
gtaaatccgc tccgagcggt 3960ggactgttca tacgggaaca ttcccatttc
tattgacatc ccgaacgctg cctttatcag 4020gacatcagat gcaccactgg
tctcaacagt caaatgtgaa gtcagtgagt gcacttattc 4080agcagacttc
ggcgggatgg ccaccctgca gtatgtatcc gaccgcgaag gtcaatgccc
4140cgtacattcg cattcgagca cagcaactct ccaagagtcg acagtacatg
tcctggagaa 4200aggagcggtg acagtacact ttagcaccgc gagtccacag
gcgaacttta tcgtatcgct 4260gtgtgggaag aagacaacat gcaatgcaga
atgtaaacca ccagctgacc atatcgtgag 4320caccccgcac aaaaatgacc
aagaatttca agccgccatc tcaaaaacat catggagttg 4380gctgtttgcc
cttttcggcg gcgcctcgtc gctattaatt ataggactta tgatttttgc
4440ttgcagcatg atgctgacta gcacacgaag atgaccgcta cgccccaatg
atccgaccag 4500caaaactcga tgtacttccg aggaactgat gtgcataatg
catcaggctg gtacattaga 4560tccccgctta ccgcgggcaa tatagcaaca
ctaaaaactc gatgtacttc cgaggaagcg 4620cagtgcataa tgctgcgcag
tgttgccaca taaccactat attaaccatt tatctagcgg 4680acgccaaaaa
ctcaatgtat ttctgaggaa gcgtggtgca taatgccacg cagcgtctgc
4740ataactttta ttatttcttt tattaatcaa caaaattttg tttttaacat
ttcaaaaaaa 4800aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa atttaaatta
attaagcggc cgcctcgagg 4860acgtcaggtg gcacttttcg gggaaatgtg
cgcggaaccc ctatttgttt atttttctaa 4920atacattcaa atatgtatcc
gctcatgaga caataaccct gataaatgct tcaataatat 4980tgaaaaagga
agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg
5040gcattttgcc ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa
agatgctgaa 5100gatcagttgg gtgcacgagt gggttacatc gaactggatc
tcaacagcgg taagatcctt 5160gagagttttc gccccgaaga acgttttcca
atgatgagca cttttaaagt tctgctatgt 5220ggcgcggtat tatcccgtat
tgacgccggg caagagcaac tcggtcgccg catacactat 5280tctcagaatg
acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg
5340acagtaagag aattatgcag tgctgccata accatgagtg ataacactgc
ggccaactta 5400cttctgacaa cgatcggagg accgaaggag ctaaccgctt
ttttgcacaa catgggggat 5460catgtaactc gccttgatcg ttgggaaccg
gagctgaatg aagccatacc aaacgacgag 5520cgtgacacca cgatgcctgt
agcaatggca acaacgttgc gcaaactatt aactggcgaa 5580ctacttactc
tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca
5640ggaccacttc tgcgctcggc ccttccggct ggctggttta ttgctgataa
atctggagcc 5700ggtgagcgtg ggtctcgcgg tatcattgca gcactggggc
cagatggtaa gccctcccgt 5760atcgtagtta tctacacgac ggggagtcag
gcaactatgg atgaacgaaa tagacagatc 5820gctgagatag gtgcctcact
gattaagcat tggtaactgt cagaccaagt ttactcatat 5880atactttaga
ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt
5940tttgataatc tcatgaccaa aatcccttaa cgtgagtttt cgttccactg
agcgtcagac 6000cccgtagaaa agatcaaagg atcttcttga gatccttttt
ttctgcgcgt aatctgctgc 6060ttgcaaacaa aaaaaccacc gctaccagcg
gtggtttgtt tgccggatca agagctacca 6120actctttttc cgaaggtaac
tggcttcagc agagcgcaga taccaaatac tgtccttcta 6180gtgtagccgt
agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct
6240ctgctaatcc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct
taccgggttg 6300gactcaagac gatagttacc ggataaggcg cagcggtcgg
gctgaacggg gggttcgtgc 6360acacagccca gcttggagcg aacgacctac
accgaactga gatacctaca gcgtgagcta 6420tgagaaagcg ccacgcttcc
cgaagggaga aaggcggaca ggtatccggt aagcggcagg 6480gtcggaacag
gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt
6540cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc
gtcagggggg 6600cggagcctat ggaaaaacgc cagcaacgcg gcctttttac
ggttcctggc cttttgctgg 6660ccttttgctc acatgtggga ggctagagta
catttaggtg acactataga a 6711396711DNASindbis virus 39attgacggcg
tagtacacac tattgaatca aacagccgac caattgcact accatcacaa 60tggagaagcc
agtagtaaac gtagacgtag acccccagag tccgtttgtc gtgcaactgc
120aaaaaagctt cccgcaattt gaggtagtag cacagcaggt cactccaaat
gaccatgcta 180atgccagagc attttcgcat ctggccagta aactaatcga
gctggaggtt cctaccacag 240cgacgatctt ggacataggc agcgcaccgg
ctcgtagaat gttttccgag caccagtatc 300attgtgtctg ccccatgcgt
agtccagaag acccggaccg catgatgaaa tatgccagta 360aactggcgga
aaaagcgtgc aagattacaa acaagaactt gcatgagaag attaaggatc
420tccggatccc ctgaaaaggc tgtttaagtt gggtaaaccg ctcccagccg
acgacgagca 480agacgaagac agaagacgcg ctctgctaga tgaaacaaag
gcgtggttta gagtaggtat 540aacaggcact ttagcagtgg ccgtgacgac
ccggtatgag gtagacaata ttacacctgt 600cctactggca ttgagaactt
ttgcccagag caaaagagca ttccaagcca tcagagggga 660aataaagcat
ctctacggtg gtcctaaata gtcagcatag tacatttcat ctgactaata
720ctacaacacc accaccatga atagaggatt ctttaacatg ctcggccgcc
gccccttccc 780ggcccccact gccatgtgga ggccgcggag aaggaggcag
gcggccccga tgcctgcccg 840caacgggctg gcttctcaaa tccagcaact
gaccacagcc gtcagtgccc tagtcattgg 900acaggcaact agacctcaac
ccccacgtcc acgccagcca ccgcgccaga agaagcaggc 960gcccaagcaa
ccaccgaagc cgaagaaacc aaaaacgcag gagaagaaga agaagcaacc
1020tgcaaaaccc aaacccggaa agagacagcg catggcactt aagttggagg
ccgacagatt 1080gttcgacgtc aagaacgagg acggagatgt catcgggcac
gcactggcca tggaaggaaa 1140ggtaatgaaa cctctgcacg tgaaaggaac
catcgaccac cctgtgctat caaagctcaa 1200atttaccaag tcgtcagcat
acgacatgga gttcgcacag ttgccagtca acatgagaag 1260tgaggcattc
acctacacca gtgaacaccc cgaaggattc tataactggc accacggagc
1320ggtgcagtat agtggaggta gatttaccat ccctcgcgga gtaggaggca
gaggagacag 1380cggtcgtccg atcatggata actccggtcg ggttgtcgcg
atagtcctcg gtggagctga 1440tgaaggaaca cgaactgccc tttcggtcgt
cacctggaat agtaaaggga agacaattaa 1500gacgaccccg gaagggacag
aagagtggtc cgcagcacca ctggtcacgg caatgtgttt 1560gctcggaaat
gtgagcttcc catgcgaccg cccgcccaca tgctataccc gcgaaccttc
1620cagagccctc gacatccttg aagagaacgt gaaccatgag gcctacgata
ccctgctcaa 1680tgccatattg cggtgcggat cgtctggcag aagcaaaaga
agcgtcatcg atgactttac 1740cctgaccagc ccctacttgg gcacatgctc
gtactgccac catactgaac cgtgcttcag 1800ccctgttaag atcgagcagg
tctgggacga agcggacgat aacaccatac gcatacagac 1860ttccgcccag
tttggatacg accaaagcgg agcagcaagc gcaaacaagt accgctacat
1920gtcgcttaag caggatcaca ccgttaaaga aggcaccatg gatgacatca
agattagcac 1980ctcaggaccg tgtagaaggc ttagctacaa aggatacttt
ctcctcgcaa aatgccctcc 2040aggggacagc gtaacggtta gcatagtgag
tagcaactca gcaacgtcat gtacactggc 2100ccgcaagata aaaccaaaat
tcgtgggacg ggaaaaatat gatctacctc ccgttcacgg 2160taaaaaaatt
ccttgcacag tgtacgaccg tctgaaagaa acaactgcag gctacatcac
2220tatgcacagg ccgggcccgc acgcttatac atcctacctg gaagaatcat
cagggaaagt 2280ttacgcaaag ccgccatctg ggaagaacat tacgtatgag
tgcaagtgcg gcgactacaa 2340gaccggaacc gtttcgaccc gcaccgaaat
cactggttgc accgccatca agcagtgcgt 2400cgcctataag agcgaccaaa
cgaagtgggt cttcaactca ccggacttga tccgacatga 2460cgaccacacg
gtccaaggga aattgcattt gcctttcaag ttgatcccga gtacctgcat
2520ggtccctgtt gcccacgcgc cgaatgtaat acatggcttt aaacacatca
gcctccaatt 2580agatacagac cacttgacat tgctcaccac caggagacta
ggggcaaacc cggaaccaac 2640cactgaatgg atcgtcggaa agacggtcag
aaacttcacc gtcgaccgag atggcctgga 2700atacatatgg ggaaatcatg
agccagtgag ggtctatgcc caagagtcag caccaggaga 2760ccctcacgga
tggccacacg aaatagtaca gcattactac catcgccatc ctgtgtacac
2820catcttagcc gtcgcatcag ctaccgtggc gatgatgatt ggcgtaactg
ttgcagtgtt 2880atgtgcctgt aaagcgcgcc gtgagtgcct gacgccatac
gccctggccc caaacgccgt 2940aatcccaact tcgctggcac tcttgtgctg
cgttaggtcg gccaatgctg aaacgttcac 3000cgagaccatg agttacttgt
ggtcgaacag tcagccgttc ttctgggtcc agttgtgcat 3060acctttggcc
gctttcatcg ttctaatgcg ctgctgctcc tgctgcctgc cttttttagt
3120ggttgccggc gcctacctgg cgaaggtaga cgcctacgaa catgcgacca
ctgttccaaa 3180tgtgccacag ataccgtata aggcacttgt tgaaagggca
gggtatgccc cgctcaattt 3240ggagatcact gtcatgtcct cggaggtttt
gccttccacc aaccaagagt acattacctg 3300caaattcacc actgtggtcc
cctccccaaa aatcaaatgc tgcggctcct tggaatgtca 3360gccggccgtt
catgcagact atacctgcaa ggtcttcgga ggggtctacc cctttatgtg
3420gggaggagcg caatgttttt gcgacagtga gaacagccag atgagtgagg
cgtacgtcga 3480actgtcagca gattgcgcgt ctgaccacgc gcaggcgatt
aaggtgcaca ctgccgcgat 3540gaaagtagga ctgcgtatag tgtacgggaa
cactaccagt ttcctagatg tgtacgtgaa 3600cggagtcaca ccaggaacgt
ctaaagactt gaaagtcata gctggaccaa tttcagcatc 3660gtttacgcca
ttcgatcata aggtcgttat ccatcgcggc ctggtgtaca actatgactt
3720cccggaatat ggagcgatga aaccaggagc gtttggagac attcaagcta
cctccttgac 3780tagcaaggat ctcatcgcca gcacagacat taggctactc
aagccttccg ccaagaacgt 3840gcatgtcccg tacacgcagg ccgcatcagg
atttgagatg tggaaaaaca actcaggccg 3900cccactgcag gaaaccgcac
ctttcgggtg taagattgca gtaaatccgc tccgagcggt 3960ggactgttca
tacgggaaca ttcccatttc tattgacatc ccgaacgctg cctttatcag
4020gacatcagat gcaccactgg tctcaacagt caaatgtgaa gtcagtgagt
gcacttattc 4080agcagacttc ggcgggatgg ccaccctgca gtatgtatcc
gaccgcgaag gtcaatgccc 4140cgtacattcg cattcgagca cagcaactct
ccaagagtcg acagtacatg tcctggagaa 4200aggagcggtg acagtacact
ttagcaccgc gagtccacag gcgaacttta tcgtatcgct 4260gtgtgggaag
aagacaacat gcaatgcaga atgtaaacca ccagctgacc atatcgtgag
4320caccccgcac aaaaatgacc aagaatttca agccgccatc tcaaaaacat
catggagttg 4380gctgtttgcc cttttcggcg gcgcctcgtc gctattaatt
ataggactta tgatttttgc 4440ttgcagcatg atgctgacta gcacacgaag
atgaccgcta cgccccaatg atccgaccag 4500caaaactcga tgtacttccg
aggaactgat gtgcataatg catcaggctg gtacattaga 4560tccccgctta
ccgcgggcaa tatagcaaca ctaaaaactc gatgtacttc cgaggaagcg
4620cagtgcataa tgctgcgcag tgttgccaca taaccactat attaaccatt
tatctagcgg 4680acgccaaaaa ctcaatgtat ttctgaggaa gcgtggtgca
taatgccacg cagcgtctgc 4740ataactttta ttatttcttt tattaatcaa
caaaattttg tttttaacat ttcaaaaaaa 4800aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa atttaaatta attaagcggc cgcctcgagg 4860acgtcaggtg
gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa
4920atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct
tcaataatat 4980tgaaaaagga agagtatgag tattcaacat ttccgtgtcg
cccttattcc cttttttgcg 5040gcattttgcc ttcctgtttt tgctcaccca
gaaacgctgg tgaaagtaaa agatgctgaa 5100gatcagttgg gtgcacgagt
gggttacatc gaactggatc tcaacagcgg taagatcctt 5160gagagttttc
gccccgaaga acgttttcca atgatgagca cttttaaagt tctgctatgt
5220ggcgcggtat tatcccgtat tgacgccggg caagagcaac tcggtcgccg
catacactat 5280tctcagaatg acttggttga gtactcacca gtcacagaaa
agcatcttac ggatggcatg 5340acagtaagag aattatgcag tgctgccata
accatgagtg ataacactgc ggccaactta 5400cttctgacaa cgatcggagg
accgaaggag ctaaccgctt ttttgcacaa catgggggat 5460catgtaactc
gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag
5520cgtgacacca cgatgcctgt agcaatggca acaacgttgc gcaaactatt
aactggcgaa 5580ctacttactc tagcttcccg gcaacaatta atagactgga
tggaggcgga taaagttgca 5640ggaccacttc tgcgctcggc ccttccggct
ggctggttta ttgctgataa atctggagcc 5700ggtgagcgtg ggtctcgcgg
tatcattgca gcactggggc cagatggtaa gccctcccgt 5760atcgtagtta
tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc
5820gctgagatag gtgcctcact gattaagcat tggtaactgt cagaccaagt
ttactcatat 5880atactttaga ttgatttaaa acttcatttt taatttaaaa
ggatctaggt gaagatcctt 5940tttgataatc tcatgaccaa aatcccttaa
cgtgagtttt cgttccactg agcgtcagac 6000cccgtagaaa agatcaaagg
atcttcttga gatccttttt ttctgcgcgt aatctgctgc 6060ttgcaaacaa
aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca
6120actctttttc cgaaggtaac tggcttcagc agagcgcaga taccaaatac
tgtccttcta 6180gtgtagccgt agttaggcca ccacttcaag aactctgtag
caccgcctac atacctcgct 6240ctgctaatcc tgttaccagt ggctgctgcc
agtggcgata agtcgtgtct taccgggttg 6300gactcaagac gatagttacc
ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc 6360acacagccca
gcttggagcg aacgacctac accgaactga gatacctaca gcgtgagcta
6420tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt
aagcggcagg 6480gtcggaacag gagagcgcac gagggagctt ccagggggaa
acgcctggta tctttatagt 6540cctgtcgggt ttcgccacct ctgacttgag
cgtcgatttt tgtgatgctc gtcagggggg 6600cggagcctat ggaaaaacgc
cagcaacgcg gcctttttac ggttcctggc cttttgctgg 6660ccttttgctc
acatgtggga ggctagagta catttaggtg acactataga a 6711406711DNASindbis
virus 40attgacggcg tagtacacac tattgaatca aacagccgac caattgcact
accatcacaa 60tggagaagcc agtagtaaac gtagacgtag acccccagag tccgtttgtc
gtgcaactgc 120aaaaaagctt cccgcaattt gaggtagtag cacagcaggt
cactccaaat gaccatgcta 180atgccagagc attttcgcat ctggccagta
aactaatcga gctggaggtt cctaccacag 240cgacgatctt ggacataggc
agcgcaccgg ctcgtagaat gttttccgag caccagtatc 300attgtgtctg
ccccatgcgt agtccagaag acccggaccg catgatgaaa tatgccagta
360aactggcgga aaaagcgtgc aagattacaa acaagaactt gcatgagaag
attaaggatc 420tccggatccc ctgaaaaggc tgtttaagtt gggtaaaccg
ctcccagccg acgacgagca 480agacgaagac agaagacgcg ctctgctaga
tgaaacaaag gcgtggttta gagtaggtat 540aacaggcact ttagcagtgg
ccgtgacgac ccggtatgag gtagacaata ttacacctgt 600cctactggca
ttgagaactt ttgcccagag caaaagagca ttccaagcca tcagagggga
660aataaagcat ctctacggtg gtcctaaata gtcagcatag tacatttcat
ctgactaata 720ctacaacacc accaccatga atagaggatt ctttaacatg
ctcggccgcc gccccttccc 780ggcccccact gccatgtgga ggccgcggag
aaggaggcag gcggccccga tgcctgcccg 840caacgggctg gcttctcaaa
tccagcaact gaccacagcc gtcagtgccc tagtcattgg 900acaggcaact
agacctcaac ccccacgtcc acgccagcca ccgcgccaga agaagcaggc
960gcccaagcaa ccaccgaagc cgaagaaacc aaaaacgcag gagaagaaga
agaagcaacc 1020tgcaaaaccc aaacccggaa agagacagcg catggcactt
aagttggagg ccgacagatt 1080gttcgacgtc aagaacgagg acggagatgt
catcgggcac gcactggcca tggaaggaaa 1140ggtaatgaaa cctctgcacg
tgaaaggaac catcgaccac cctgtgctat caaagctcaa 1200atttaccaag
tcgtcagcat acgacatgga gttcgcacag ttgccagtca acatgagaag
1260tgaggcattc acctacacca gtgaacaccc cgaaggattc tataactggc
accacggagc 1320ggtgcagtat agtggaggta gatttaccat ccctcgcgga
gtaggaggca gaggagacag 1380cggtcgtccg atcatggata actccggtcg
ggttgtcgcg atagtcctcg gtggagctga 1440tgaaggaaca cgaactgccc
tttcggtcgt cacctggaat agtaaaggga agacaattaa 1500gacgaccccg
gaagggacag aagagtggtc cgcagcacca ctggtcacgg caatgtgttt
1560gctcggaaat gtgagcttcc catgcgaccg cccgcccaca tgctataccc
gcgaaccttc 1620cagagccctc gacatccttg aagagaacgt gaaccatgag
gcctacgata ccctgctcaa 1680tgccatattg cggtgcggat cgtctggcag
aagcaaaaga agcgtcactg acgactttac 1740cctgaccagc ccctacttgg
gcacatgctc gtactgccac catactgaac cgtgcttcag 1800ccctgttaag
atcgagcagg tctgggacga agcggacgat aacaccatac gcatacagac
1860ttccgcccag tttggatacg accaaagcgg agcagcaagc gcaaacaagt
accgctacat 1920gtcgcttaag caggatcaca ccgttaaaga aggcaccatg
gatgacatca agattagcac 1980ctcaggaccg tgtagaaggc ttagctacaa
aggatacttt ctcctcgcaa aatgccctcc 2040aggggacagc gtaacggtta
gcatagtgag tagcaactca gcaacgtcat gtacactggc 2100ccgcaagata
aaaccaaaat tcgtgggacg ggaaaaatat gatctacctc ccgttcacgg
2160taaaaaaatt ccttgcacag tgtacgaccg tctgaaagaa acaactgcag
gctacatcac 2220tatgcacagg ccgggaccgc acgcttatac atcctacctg
aaagaatcat cagggaaagt 2280ttacgcaaag ccgccatctg ggaagaacat
tacgtatgag tgcaagtgcg gcgactacaa 2340gaccggaacc gtttcgaccc
gcaccgaaat cactggttgc accgccatca agcagtgcgt 2400cgcctataag
agcgaccaaa cgaagtgggt cttcaactca ccggacttga tccgacatga
2460cgaccacacg gtccaaggga aattgcattt gcctttcaag ttgatcccga
gtacctgcat 2520ggtccctgtt gcccacgcgc cgaatgtaat acatggcttt
aaacacatca gcctccaatt 2580agatacagac cacttgacat tgctcaccac
caggagacta ggggcaaacc cggaaccaac 2640cactgaatgg atcgtcggaa
agacggtcag aaacttcacc gtcgaccgag atggcctgga 2700atacatatgg
ggaaatcatg agccagtgag ggtctatgcc caagagtcag caccaggaga
2760ccctcacgga tggccacacg aaatagtaca gcattactac catcgccatc
ctgtgtacac 2820catcttagcc gtcgcatcag ctaccgtggc gatgatgatt
ggcgtaactg ttgcagtgtt 2880atgtgcctgt aaagcgcgcc gtgagtgcct
gacgccatac gccctggccc caaacgccgt 2940aatcccaact tcgctggcac
tcttgtgctg cgttaggtcg gccaatgctg aaacgttcac 3000cgagaccatg
agttacttgt ggtcgaacag tcagccgttc ttctgggtcc agttgtgcat
3060acctttggcc gctttcatcg ttctaatgcg ctgctgctcc tgctgcctgc
cttttttagt 3120ggttgccggc gcctacctgg cgaaggtaga cgcctacgaa
catgcgacca ctgttccaaa 3180tgtgccacag ataccgtata aggcacttgt
tgaaagggca gggtatgccc cgctcaattt 3240ggagatcact gtcatgtcct
cggaggtttt gccttccacc aaccaagagt acattacctg 3300caaattcacc
actgtggtcc cctccccaaa aatcaaatgc tgcggctcct tggaatgtca
3360gccggccgtt catgcagact atacctgcaa ggtcttcgga ggggtctacc
cctttatgtg 3420gggaggagcg caatgttttt gcgacagtga gaacagccag
atgagtgagg cgtacgtcga 3480actgtcagca gattgcgcgt ctgaccacgc
gcaggcgatt aaggtgcaca ctgccgcgat 3540gaaagtagga ctgcgtatag
tgtacgggaa cactaccagt ttcctagatg tgtacgtgaa 3600cggagtcaca
ccaggaacgt ctaaagactt gaaagtcata gctggaccaa tttcagcatc
3660gtttacgcca ttcgatcata aggtcgttat ccatcgcggc ctggtgtaca
actatgactt 3720cccggaatat ggagcgatga aaccaggagc gtttggagac
attcaagcta cctccttgac 3780tagcaaggat ctcatcgcca gcacagacat
taggctactc aagccttccg ccaagaacgt 3840gcatgtcccg tacacgcagg
ccgcatcagg atttgagatg tggaaaaaca actcaggccg 3900cccactgcag
gaaaccgcac ctttcgggtg taagattgca gtaaatccgc tccgagcggt
3960ggactgttca tacgggaaca ttcccatttc tattgacatc ccgaacgctg
cctttatcag 4020gacatcagat gcaccactgg tctcaacagt caaatgtgaa
gtcagtgagt gcacttattc 4080agcagacttc ggcgggatgg ccaccctgca
gtatgtatcc gaccgcgaag gtcaatgccc 4140cgtacattcg cattcgagca
cagcaactct ccaagagtcg acagtacatg tcctggagaa 4200aggagcggtg
acagtacact ttagcaccgc gagtccacag gcgaacttta tcgtatcgct
4260gtgtgggaag aagacaacat gcaatgcaga atgtaaacca ccagctgacc
atatcgtgag 4320caccccgcac aaaaatgacc aagaatttca agccgccatc
tcaaaaacat catggagttg 4380gctgtttgcc cttttcggcg gcgcctcgtc
gctattaatt ataggactta tgatttttgc 4440ttgcagcatg atgctgacta
gcacacgaag atgaccgcta cgccccaatg atccgaccag 4500caaaactcga
tgtacttccg aggaactgat gtgcataatg catcaggctg gtacattaga
4560tccccgctta ccgcgggcaa tatagcaaca ctaaaaactc gatgtacttc
cgaggaagcg 4620cagtgcataa tgctgcgcag tgttgccaca taaccactat
attaaccatt tatctagcgg 4680acgccaaaaa ctcaatgtat ttctgaggaa
gcgtggtgca taatgccacg cagcgtctgc 4740ataactttta ttatttcttt
tattaatcaa caaaattttg tttttaacat ttcaaaaaaa 4800aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa atttaaatta attaagcggc cgcctcgagg
4860acgtcaggtg gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt
atttttctaa 4920atacattcaa atatgtatcc gctcatgaga caataaccct
gataaatgct tcaataatat 4980tgaaaaagga agagtatgag tattcaacat
ttccgtgtcg cccttattcc cttttttgcg 5040gcattttgcc ttcctgtttt
tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa 5100gatcagttgg
gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt
5160gagagttttc gccccgaaga acgttttcca atgatgagca cttttaaagt
tctgctatgt 5220ggcgcggtat tatcccgtat tgacgccggg caagagcaac
tcggtcgccg catacactat 5280tctcagaatg acttggttga gtactcacca
gtcacagaaa agcatcttac ggatggcatg 5340acagtaagag aattatgcag
tgctgccata accatgagtg ataacactgc ggccaactta 5400cttctgacaa
cgatcggagg accgaaggag ctaaccgctt ttttgcacaa catgggggat
5460catgtaactc gccttgatcg ttgggaaccg gagctgaatg aagccatacc
aaacgacgag 5520cgtgacacca cgatgcctgt agcaatggca acaacgttgc
gcaaactatt aactggcgaa 5580ctacttactc tagcttcccg gcaacaatta
atagactgga tggaggcgga taaagttgca 5640ggaccacttc tgcgctcggc
ccttccggct ggctggttta ttgctgataa atctggagcc 5700ggtgagcgtg
ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgt
5760atcgtagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa
tagacagatc 5820gctgagatag gtgcctcact gattaagcat tggtaactgt
cagaccaagt ttactcatat 5880atactttaga ttgatttaaa acttcatttt
taatttaaaa ggatctaggt gaagatcctt 5940tttgataatc tcatgaccaa
aatcccttaa cgtgagtttt cgttccactg agcgtcagac 6000cccgtagaaa
agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc
6060ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca
agagctacca 6120actctttttc cgaaggtaac tggcttcagc agagcgcaga
taccaaatac tgtccttcta 6180gtgtagccgt agttaggcca ccacttcaag
aactctgtag caccgcctac atacctcgct 6240ctgctaatcc tgttaccagt
ggctgctgcc agtggcgata agtcgtgtct taccgggttg 6300gactcaagac
gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc
6360acacagccca gcttggagcg aacgacctac accgaactga gatacctaca
gcgtgagcta 6420tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca
ggtatccggt aagcggcagg 6480gtcggaacag gagagcgcac gagggagctt
ccagggggaa acgcctggta tctttatagt 6540cctgtcgggt ttcgccacct
ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg 6600cggagcctat
ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg
6660ccttttgctc acatgtggga ggctagagta catttaggtg acactataga a
6711
* * * * *